<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Inherited platelet function disorders (IPFDs)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Inherited platelet function disorders (IPFDs)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Inherited platelet function disorders (IPFDs)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gillian Lowe, MA MB BChir, MRCP, FRCPath</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Catherine Hayward, MD, PhD, FRCPC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark Crowther, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Platelet function disorders include heritable and acquired conditions of varying severity. Some are associated with thrombocytopenia, and some have a normal platelet count. </p><p>Evaluation can be challenging. These disorders are rare, bleeding severity varies, and clinicians are often unfamiliar with the appropriate evaluation and treatment. </p><p>This topic reviews inherited platelet disorders, with a focus on inherited platelet function disorders (IPFDs). </p><p>Separate topics discuss:</p><p class="bulletIndent1"><span class="glyph">●</span>Biology of platelets and anti-platelet drugs – (See  <a class="medical medical_review" href="/d/html/6683.html" rel="external">"Platelet biology and mechanism of anti-platelet drugs"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet function testing – (See  <a class="medical medical_review" href="/d/html/4433.html" rel="external">"Platelet function testing"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia evaluation (child) – (See  <a class="medical medical_review" href="/d/html/5939.html" rel="external">"Approach to the child with unexplained thrombocytopenia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia evaluation (adult) – (See  <a class="medical medical_review" href="/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding evaluation (child) – (See  <a class="medical medical_review" href="/d/html/5936.html" rel="external">"Approach to the child with bleeding symptoms"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding evaluation (adult) – (See  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CONCEPTUAL FRAMEWORK</span><span class="headingEndMark"> — </span>IPFDs can be categorized according to clinical phenotype (platelet size and morphology; associated with or without thrombocytopenia, and/or syndromic features) or mechanism (which gene variants cause the disorder and/or which aspect of platelet function they disrupt).</p><p>Severity of bleeding is important clinically but can vary widely, even among individuals with the same IPFD, possibly due to the specific genetic variant, other heritable variants that may influence bleeding risk, comorbidities, and the bleeding challenges to which the individual has been exposed.</p><p class="headingAnchor" id="H1448893379"><span class="h2">Mechanisms and gene variants</span><span class="headingEndMark"> — </span>Platelets mediate the first phase of hemostasis (also called primary hemostasis). Different subpopulations of platelets at the site of injury may carry out different functions [<a href="#rid1">1</a>]. Ultimately a platelet plug forms at the site of blood vessel injury and provides a phospholipid surface (the external surface of the platelet plasma membrane) for activation of blood coagulation factors. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Formation of the platelet plug'</a>.)</p><p>There are four major steps in primary hemostasis; these are illustrated in the figure  (<a class="graphic graphic_figure graphicRef81908" href="/d/graphic/81908.html" rel="external">figure 1</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>Platelet adhesion to the vascular subendothelium at the site of injury</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet activation and secretion of granule contents</p><p class="bulletIndent1"><span class="glyph">●</span>Aggregation of multiple platelets</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet interactions with clotting factors, resulting in thrombin generation</p><p></p><p>Many genes have been implicated in inherited disorders of platelet number and/or function. </p><p>Some IPFDs impair platelet function, with or without a low platelet count, whereas other conditions manifest predominantly as an inherited thrombocytopenia. For conditions with few reported cases (&lt;50 cases worldwide), there can be uncertainty about the phenotypes, and a genetic variant identified after panel testing may be identified as a variant of uncertain significance (VUS) if there is not sufficient previously published literature confirming causality. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adhesion </strong>– Platelets adhere to the vascular subendothelium and von Willebrand factor (VWF) via glycoprotein (GP) receptors on the platelet surface  (<a class="graphic graphic_figure graphicRef81908" href="/d/graphic/81908.html" rel="external">figure 1</a>) [<a href="#rid2">2-9</a>]. Subendothelial components involved in platelet adhesive mechanisms include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Collagen</strong> – Receptors are integrin alpha2beta1 (previously called GPIa/IIa), and GPVI.</p><p class="bulletIndent2"><span class="glyph">•</span><strong>VWF</strong> – VWF binds to collagen, augmenting adhesion though binding to platelet GPIb/IX/V. GpIb/IX/V also contributes to platelet aggregation at high shear rates. Platelet interactions with VWF are further stabilized by integrin alphaIIbbeta3 (previously called GPIIb/IIIa).</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fibrinogen </strong>– Receptor is integrin alphaIIbbeta3. </p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fibronectin</strong> – Receptors are alpha5beta1 and alphaIIbbeta3.</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombospondin</strong> – Receptor is CD36 (also called thrombospondin receptor and macrophage scavenger receptor).</p><p></p><p class="bulletIndent1">Disorders of platelet surface receptors include Glanzmann thrombasthenia (pathogenic variants in <em>ITGA2B </em>or <em>ITGB3</em>, leading to deficiency of integrin alphaIIbbeta3) and Bernard-Soulier syndrome (pathogenic variants in <em>GP1BA, GP1BB, </em>or<em> GP9</em>, leading to deficiency of GP Ib/IX/V). (See <a class="local">'Glanzmann thrombasthenia'</a> below and <a class="local">'Bernard-Soulier syndrome'</a> below.) </p><p></p><p class="bulletIndent1">IPFDs due to disorders in platelet collagen receptors are rare.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Activation and aggregation</strong> – Activation is the process by which signaling pathways lead to shape change, altered surface receptors, and release of platelet granule contents. This causes platelets to aggregate with other platelets and form the primary hemostatic plug. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Platelet aggregation'</a>.) </p><p></p><p class="bulletIndent1">Platelets can be activated by a variety of agonists including thrombin, epinephrine, adenosine diphosphate (ADP), synthetic analogues of thromboxane A<sub>2</sub>, collagen, and epinephrine. Pathogenic variants causing IPFDs have been reported in some of the genes for these agonist receptors, including the receptors for ADP, collagen, and thromboxane A<sub>2</sub>. Ristocetin agglutinates platelets by promoting VWF binding to GP Ib/IX/V, which leads to "outside-in signaling" that triggers aggregation. Platelet aggregation in response to agonists and ristocetin are evaluated by platelet aggregometry  (<a class="graphic graphic_figure graphicRef56188" href="/d/graphic/56188.html" rel="external">figure 2</a>). (See  <a class="medical medical_review" href="/d/html/4433.html" rel="external">"Platelet function testing", section on 'Platelet aggregometry'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Agonists and second messenger signaling</strong> – Each agonist binds to its distinct cell surface receptor, leading to multiple downstream effects. (See  <a class="medical medical_review" href="/d/html/6683.html" rel="external">"Platelet biology and mechanism of anti-platelet drugs", section on 'Platelet receptors and their agonists'</a> and  <a class="medical medical_review" href="/d/html/6683.html" rel="external">"Platelet biology and mechanism of anti-platelet drugs", section on 'Second messenger signaling'</a>.)</p><p></p><p class="bulletIndent2">Steps include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Platelet activation ("outside-in signaling") results in calcium-dependent cytoskeletal changes and alters platelet shape.</p><p class="bulletIndent3"><span class="glyph">-</span>Conformational changes in integrin alphaIIbbeta3 ("inside out signaling") allows it to bind fibrinogen on adjacent platelets and mediate low shear aggregation.</p><p class="bulletIndent3"><span class="glyph">-</span>Release of granule contents furthers activation.</p><p></p><p class="bulletIndent2">Glanzmann thrombasthenia platelets do not aggregate with most agonists and only agglutinate with ristocetin, so the "aggregation" wave with ristocetin is reduced. (See <a class="local">'Glanzmann thrombasthenia'</a> below.)</p><p></p><p class="bulletIndent2">Bernard-Soulier platelets do not bind to VWF and do not agglutinate and aggregate with ristocetin, but they have normal alphaIIbbeta3-mediated aggregation responses. (See <a class="local">'Bernard-Soulier syndrome'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Granules </strong>–<strong> </strong>Granule biogenesis is discussed separately. (See  <a class="medical medical_review" href="/d/html/6672.html" rel="external">"Megakaryocyte biology and platelet production", section on 'Granules'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Alpha granules</strong> – Alpha granules are the protein storage organelle of platelets. They contain VWF, factor V, multimerin 1, platelet factor 4, thrombospondin, fibrinogen, beta-thromboglobulin, platelet-derived growth factor, P-selectin, and other proteins.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dense granules</strong> – Dense granules contain calcium, ADP, ATP, serotonin, polyphosphate, and P-selectin [<a href="#rid10">10</a>]. Polyphosphate released from dense granules promotes coagulation via enhancing effects on factors XII and XI (contact factors) and factor V, and inhibiting tissue factor pathway inhibitor (TFPI) and thrombin activatable fibrinolysis inhibitor (TAFI) [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Control mechanisms and termination of clotting'</a>.)</p><p></p><p class="bulletIndent2">Platelet granule disorders (also called "storage pool disorders") include: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Gray platelet syndrome, in which alpha granules are deficient. (See <a class="local">'Gray platelet syndrome'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Dense (or delta) granule deficiency, the most common storage pool disorder. There are nonsyndromic and syndromic forms; the syndromic forms (which are rarer) include Chediak-Higashi syndrome and Hermansky-Pudlak syndrome. (See <a class="local">'Chediak-Higashi syndrome'</a> below and <a class="local">'Hermansky-Pudlak syndrome'</a> below.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Combined alpha-delta storage pool deficiency is an IPFD with thrombocytopenia that has both dominant and recessive forms.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Quebec platelet disorder. This is a different type of storage pool disorder that leads to abnormal, plasmin-mediated proteolysis of diverse proteins (including factor V) stored in platelet alpha granules. This is due to overexpression and increased storage of urokinase-type plasminogen activator (uPA) within megakaryocytes and platelets. It causes a platelet-dependent gain-of-function defect in fibrinolysis. (See <a class="local">'Quebec platelet disorder'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Membrane changes</strong> – Some IPFDs impair the ability of platelets to promote coagulation [<a href="#rid1">1</a>]. The activation of platelets by strong agonists (eg, combined stimulation by thrombin and collagen) alters the phospholipid distribution on platelet membranes and promotes the assembly of phospholipid-dependent coagulation factor complexes on the platelet surface. This procoagulant change involves the loss of platelet membrane phospholipid asymmetry, with movement of the negatively charged phospholipids phosphatidyl serine (PS) and phosphatidyl ethanolamine (PE) that are normally sequestered on the inner leaflet of the platelet membrane to the outer membrane leaflet, which promotes assembly of tenase and prothrombinase complexes [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The most severe is in Scott syndrome, which results from deficiency of the "flippase" enzyme that normally redistributes PS and PE to the outer leaflet of the platelet membrane with activation. (See <a class="local">'Scott syndrome'</a> below.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Less-severe platelet procoagulant function disorders include Quebec platelet disorder, Hermansky-Pudlak syndrome, and commonly encountered platelet disorders that impair aggregation responses to multiple agonists and/or cause dense granule deficiency, including familial platelet disorder with predisposition to myeloid malignancy. (See <a class="local">'Quebec platelet disorder'</a> below and <a class="local">'Hermansky-Pudlak syndrome'</a> below and  <a class="medical medical_review" href="/d/html/93183.html" rel="external">"Familial disorders of acute leukemia and myelodysplastic syndromes", section on 'Familial platelet disorder with propensity to myeloid malignancies (FPD)'</a>.)</p><p></p><p>Some IPFDs are extremely rare recessive disorders (with &lt;50 patients worldwide), including those caused by pathogenic variants in <em>SLFN14 </em>(encodes a protein of unclear function), <em>P2RY12</em> (encodes platelet P2Y<sub>12</sub> receptor), <em>FYB1</em> (encodes a protein involved in platelet activation), and <em>EPHB2</em> (encodes a receptor tyrosine kinase in platelets) [<a href="#rid11">11-15</a>]. Many of the more commonly encountered IPFDs that increase risks for bleeding have an unknown genetic cause [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H735669566"><span class="h2">Clinical spectrum (thrombocytopenia, platelet size, syndromic features)</span><span class="headingEndMark"> — </span>Many IPFDs are associated with thrombocytopenia (and/or low normal platelet counts in some affected persons), whereas some have a normal platelet count. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleeding risk</strong> – Bleeding scores are higher in IPFDs than in inherited thrombocytopenias without defective platelet function [<a href="#rid17">17</a>]. </p><p></p><p class="bulletIndent1">The absence of thrombocytopenia cannot be used to determine bleeding risk as some IPFDs with a normal platelet count have severe platelet dysfunction (eg, Glanzmann thrombasthenia). An inherited cause should be suspected if there is longstanding bleeding that is disproportionate to the thrombocytopenia and/or other features suggestive of an IPFD (syndromic features, multiple relatives with thrombocytopenia).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet count</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IPFDs with</strong> <strong>thrombocytopenia </strong>(platelet count may be normal in some of these, as indicated):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>ANKRD26-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>ARPC1B deficiency (may have normal platelet count)</p><p class="bulletIndent3"><span class="glyph">-</span>Bernard-Soulier syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>Congenital autosomal recessive small-platelet thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>Erythrokeratosis with thrombocytopenia syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>ETV6-related thrombocytopenia and leukemia predisposition (may have normal platelet count)</p><p class="bulletIndent3"><span class="glyph">-</span>Familial platelet disorder with predisposition to myeloid malignancy (may have normal platelet count)</p><p class="bulletIndent3"><span class="glyph">-</span>FLNA-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>GALE-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>GATA1 X-linked thrombocytopenia with dyserythropoietic anemia</p><p class="bulletIndent3"><span class="glyph">-</span>GFI1b-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>GNE myopathy with congenital thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>GPVI-related disease (may have normal platelet count)</p><p class="bulletIndent3"><span class="glyph">-</span>Gray platelet syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>ITGA2/ITG3B-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>MYH9-related disease</p><p class="bulletIndent3"><span class="glyph">-</span>Paris-Trousseau and Jacobsen syndrome </p><p class="bulletIndent3"><span class="glyph">-</span>Platelet-type von Willebrand disease (may have normal platelet count)</p><p class="bulletIndent3"><span class="glyph">-</span>PTPRJ-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>PRKACG-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>Noonan syndrome (may have normal platelet count)</p><p class="bulletIndent3"><span class="glyph">-</span>Quebec platelet disorder (may have normal platelet count)</p><p class="bulletIndent3"><span class="glyph">-</span>SLC35A1-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>SLFN14-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>Stormorken syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>Stormorken syndrome/York platelet syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>Thrombocytopenia with absent radius syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>Thrombocytopenia-2</p><p class="bulletIndent3"><span class="glyph">-</span>Thrombocytopenia, anemia and myelofibrosis syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>TPM4-related thrombocytopenia (may have normal platelet count)</p><p class="bulletIndent3"><span class="glyph">-</span>TRPM7-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>TUBB1-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>Wiskott-Aldrich syndrome/X-linked thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>Wiskott-Aldrich syndrome 2</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IPFDs with normal platelet counts</strong> [<a href="#rid18">18</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Arthrogryposis-renal dysfunction-cholestasis syndrome </p><p class="bulletIndent3"><span class="glyph">-</span>Autism with platelet dense granule defect</p><p class="bulletIndent3"><span class="glyph">-</span>Aspirin-like syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>Chediak-Higashi syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>Cytosolic phospholipase A2 syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>Ephrin type-B receptor 2-related disease</p><p class="bulletIndent3"><span class="glyph">-</span>Glanzmann thrombasthenia</p><p class="bulletIndent3"><span class="glyph">-</span>Ghosal syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>Hermansky-Pudlak syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>Leukocyte adhesion deficiency-III</p><p class="bulletIndent3"><span class="glyph">-</span>P2Y12-related disease</p><p class="bulletIndent3"><span class="glyph">-</span>Scott syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>TxA<sub>2</sub> receptor-related disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet size</strong> - IPFDs can be categorized by platelet size (which is a hereditary trait) since some are associated with giant platelets and some with small platelets. However, platelet size is not always reported on complete blood count (CBC) results, it may be unreliable, and in many cases the clinician will not have access to timely review of the peripheral blood smear. Sometimes the blood smear report will mention large platelets or megathrombocytes (platelet similar in size or larger than red blood cells). Some automated CBC machines may incorrectly count very large platelets as other cell types, which can affect platelet count and platelet size results. (See  <a class="medical medical_review" href="/d/html/4430.html" rel="external">"Automated complete blood count (CBC)", section on 'Platelet parameters'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Large platelets</strong> (high mean platelet volume [MPV]):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Bernard-Soulier syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>FLNA-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>GFI1b-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>Gale-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>GNE myopathy with congenital thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>Gray platelet syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>ITGA2/ITGB3-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>MYH9-related disease</p><p class="bulletIndent3"><span class="glyph">-</span>Paris-Trousseau syndrome </p><p class="bulletIndent3"><span class="glyph">-</span>Thrombocytopenia, anemia, and myelofibrosis syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>SLC35A1-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>SLFN14-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>TPM4-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>TRPM7-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>TUBB1-related thrombocytopenia</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Small platelets</strong> (low MPV):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>ARPC1B deficiency</p><p class="bulletIndent3"><span class="glyph">-</span>Congenital autosomal recessive small-platelet thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>PTPRJ-related thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>Wiskott-Aldrich syndrome (but not Wiskott-Aldrich syndrome 2)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normal size platelets</strong>:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Most IPFDs with normal platelet counts</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syndromic features </strong>– Some IPFDs only affect platelets, whereas others affect other cells or organs and present with syndromic features (some or all syndromic features may be present) [<a href="#rid19">19</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ANKRD-26-related thrombocytopenia – Leukocytosis, polycythemia, leukemia predisposition</p><p class="bulletIndent2"><span class="glyph">•</span>ARPC1B deficiency – Allergies, autoimmunity, eczema, vasculitis</p><p class="bulletIndent2"><span class="glyph">•</span>Arthrogryposis-renal dysfunction-cholestasis syndrome – Arthrogryposis, renal dysfunction, cholestasis, growth failure, cardiac defects, ichthyosis, infections</p><p class="bulletIndent2"><span class="glyph">•</span>Autism with platelet dense granule deficiency – Autism</p><p class="bulletIndent2"><span class="glyph">•</span>Chediak-Higashi syndrome – Hypopigmentation, immunodeficiency, ataxia, neuropathy</p><p class="bulletIndent2"><span class="glyph">•</span>ETV6-related thrombocytopenia and leukemia predisposition – Macrocytosis, leukemia predisposition</p><p class="bulletIndent2"><span class="glyph">•</span>Familial platelet disorder with predisposition to myeloid malignancy – Myeloid malignancy</p><p class="bulletIndent2"><span class="glyph">•</span>FLNA-related thrombocytopenia – Otopalatodigital syndrome, brain malformation (periventricular nodular heterotopia)</p><p class="bulletIndent2"><span class="glyph">•</span>GALE-related thrombocytopenia – Neutropenia</p><p class="bulletIndent2"><span class="glyph">•</span>GATA1 X-linked thrombocytopenia with dyserythropoietic hemolytic anemia with similarity to beta-thalassemia</p><p class="bulletIndent2"><span class="glyph">•</span>Ghosal syndrome – Osteopetrosis</p><p class="bulletIndent2"><span class="glyph">•</span>GPVI-related disease – Possible autoimmune manifestations</p><p class="bulletIndent2"><span class="glyph">•</span>Hermansky-Pudlak syndrome – Hypopigmentation, pulmonary fibrosis, colitis, neutropenia, immunodeficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Jacobsen syndrome (larger deletion that also causes Paris-Trousseau syndrome) – Growth and developmental delay, intellectual disability, cardiac defects, skull dysmorphism</p><p class="bulletIndent2"><span class="glyph">•</span>MYH9-related disease – Sensorineural hearing loss, kidney disease, cataracts</p><p class="bulletIndent2"><span class="glyph">•</span>Noonan syndrome – Cardiac defects, facial dysmorphism, short stature, skeletal malformations</p><p class="bulletIndent2"><span class="glyph">•</span>SLC35A1-related thrombocytopenia – Delayed psychomotor development, ataxia, choreiform movements, epilepsy, microcephaly</p><p class="bulletIndent2"><span class="glyph">•</span>Stormorken syndrome – Immunodeficiency, muscular hypotonia, ectodermal dysplasia</p><p class="bulletIndent2"><span class="glyph">•</span>Stormorken syndrome/York platelet syndrome – Immunodeficiency, asplenia, facial dysmorphism, ichthyosis, intellectual disability, myopathy</p><p class="bulletIndent2"><span class="glyph">•</span>Thrombocytopenia absent radius (TAR) – Radial dysplasia, upper and lower limb abnormalities, cardiac, renal and central nervous system malformations</p><p class="bulletIndent2"><span class="glyph">•</span>Thrombocytopenia, anemia and myelofibrosis syndrome – Hepatosplenomegaly, anemia, myelofibrosis</p><p class="bulletIndent2"><span class="glyph">•</span>Wiskott-Aldrich syndrome and X-linked thrombocytopenia – Immunodeficiency, autoimmunity, eczema, malignancy</p><p class="bulletIndent2"><span class="glyph">•</span>Wiskott-Aldrich syndrome 2 – Autoimmunity, eczema, malignancy</p><p></p><p class="headingAnchor" id="H760409996"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H844595481"><span class="h2">When to suspect</span><span class="headingEndMark"> — </span>An IPFD may be suspected when there is a bleeding phenotype despite normal screening tests of hemostasis, bleeding disproportionate to the degree of thrombocytopenia, thrombocytopenia unresponsive to immune thrombocytopenia (ITP) therapies, multiple affected relatives, and/or syndromic features suggestive of a particular IPFD. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleeding</strong> – Includes excess bleeding or bruising (particularly numerous, large, and/or spontaneous bruises), epistaxis, heavy menstrual bleeding, and/or excessive bleeding with childbirth, invasive procedures or dental extractions [<a href="#rid20">20</a>]. Typically, IPFDs are associated with mucocutaneous bleeding and bruising, beginning soon after trauma, rather than joint and muscle bleeds or delayed soft tissue hematomas  (<a class="graphic graphic_table graphicRef77834" href="/d/graphic/77834.html" rel="external">table 1</a>); Quebec platelet disorder is an exception that causes delayed bleeding [<a href="#rid21">21</a>]. All patients should be evaluated with a bleeding assessment tool (BAT) such as the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbleedingscore.certe.nl%2F&amp;token=Nn2kz6P9LalXZBakWq4EFVy%2FtKzfMxWmVZgnncoM9zqnY8WwoOfYCEf5tSBri%2Fvl&amp;TOPIC_ID=6675" target="_blank">ISTH-BAT</a>. </p><p></p><p class="bulletIndent1">Some IPFDs have minimal bleeding symptoms, whereas others are associated with bleeding disproportionate to the degree of thrombocytopenia. IPFDs with severe bleeding typically have bleeding every hemostatic challenge, whereas milder IPFDs may have variable bleeding with hemostatic challenges. </p><p></p><p class="bulletIndent1">In general, bleeding due to an IPFD is identified earlier and more frequently in females. Females with IPFD have higher bleeding scores than males and more skin bleeding [<a href="#rid16">16,22</a>]. They also have increased bleeding related to menses and childbirth. Males may only present after bleeding with hemostatic challenges. (See <a class="local">'History and examination'</a> below.) </p><p></p><p class="bulletIndent1">Sometimes patients are referred to the bleeding disorders specialist based on their clinical history, and sometimes the primary clinician or hematologist may have done an initial evaluation and documented normal coagulation studies and negative testing for von Willebrand disease (VWD) despite excessive or disproportionate bleeding. (See  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder", section on 'Positive bleeding history and normal initial testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombocytopenia or abnormal platelet morphology </strong>– Some IPFDs are associated with thrombocytopenia. However, absence of thrombocytopenia does not exclude an IPFD, since some IPFDs have normal platelet counts. IPFDs with thrombocytopenia are sometimes erroneously presumed to be ITP, which is a diagnosis of exclusion. Thrombocytopenia unresponsive to ITP therapies is a clue to the diagnosis of an IPFD. (See <a class="local">'Clinical spectrum (thrombocytopenia, platelet size, syndromic features)'</a> above and  <a class="medical medical_review" href="/d/html/6676.html" rel="external">"Immune thrombocytopenia (ITP) in adults: Clinical manifestations and diagnosis", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1">An IPFD may be suspected if the platelet morphology (or other blood smear finding) is abnormal. Examples include agranular (gray) platelets, megathrombocytes, or Döhle bodies in neutrophils. While the blood smear can provide important clues to an IPFD, most IPFDs show normal findings on the blood smear. (See <a class="local">'CBC, blood smear, coagulation testing'</a> below and  <a class="medical medical_review" href="/d/html/4435.html" rel="external">"Evaluation of the peripheral blood smear", section on 'Platelets'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syndromic features</strong> – Some IPFDs are associated with other findings and non-hematologic features. (See <a class="local">'Clinical spectrum (thrombocytopenia, platelet size, syndromic features)'</a> above and <a class="local">'Specific disorders'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IPFD in a relative</strong> – Multiple affected relatives strongly suggests a heritable disorder. (See <a class="local">'Implications for first-degree relatives'</a> below.)</p><p></p><p class="headingAnchor" id="H71932840"><span class="h2">History and examination</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BAT</strong> – The bleeding history is best documented using a bleeding assessment tool (BAT) such as one available online from the International Society on Thrombosis and Haemostasis (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbleedingscore.certe.nl%2F&amp;token=Nn2kz6P9LalXZBakWq4EFVy%2FtKzfMxWmVZgnncoM9zqnY8WwoOfYCEf5tSBri%2Fvl&amp;TOPIC_ID=6675" target="_blank">ISTH-BAT</a>). Other BATs have been used to collect standardized data on IPFD symptoms and estimate the bleeding risks as likelihood or odds ratios, relative to the general population or unaffected relatives, as some bleeding symptoms are common in the general population [<a href="#rid16">16,21</a>].</p><p></p><p class="bulletIndent1">Advice on use of the BAT is discussed separately. (See  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder", section on 'Bleeding score'</a> and  <a class="medical medical_review" href="/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease", section on 'Evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syndromic features</strong> – History of syndromic features may suggest a specific IPFD. (See <a class="local">'Clinical spectrum (thrombocytopenia, platelet size, syndromic features)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Family history</strong> – The family history is an important consideration. IPFDs are much more common in populations where consanguinity is prevalent, and their incidence is also influenced by founder effects and (for recessive disorders) the number of carriers in the population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Examination </strong>– The examination should evaluate for evidence of bleeding, bruising, and anemia, as well as syndromic features such as skeletal, joint, or skin abnormalities (hypopigmentation, eczema, ichthyosis). An abdominal examination including liver and spleen size, as well as stigmata of chronic liver disease, may suggest a specific IPFD (eg, hepatosplenomegaly is seen with thrombocytopenia, anemia, and myelofibrosis syndrome) or an alternative diagnosis. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="headingAnchor" id="H710622088"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>The details of the evaluation depend on the individual's presenting findings (bleeding score, thrombocytopenia, syndromic findings) and whether there is a known familial bleeding disorder  (<a class="graphic graphic_algorithm graphicRef138359" href="/d/graphic/138359.html" rel="external">algorithm 1</a>). Tests for common IPFDs and rare but important IPFDs may also be considered.</p><p class="headingAnchor" id="H8"><span class="h3">CBC, blood smear, coagulation testing</span><span class="headingEndMark"> — </span>The complete blood count (CBC) documents presence or absence of thrombocytopenia and abnormalities of white blood cells (WBCs) and/or red blood cells (RBCs). The WBC count, RBC count, and hemoglobin are typically normal in IPFDs unless there is iron deficiency anemia or a disorder that also affects WBCs or RBCs. (See <a class="local">'Specific disorders'</a> below.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet count </strong>– The platelet count helps distinguish IPFDs associated with thrombocytopenia from those without. The discussion above classified IPFDs according to whether thrombocytopenia is present. (See <a class="local">'Clinical spectrum (thrombocytopenia, platelet size, syndromic features)'</a> above.)</p><p></p><p class="bulletIndent1">In some individuals, thrombocytopenia may be due to an acquired condition. (See <a class="local">'Differential diagnosis'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet size and blood smear review</strong> – Information about platelet size and granulation may be helpful if available, but some clinicians may not have access to this information (it may not be included in the automated CBC report) or the ability to review the blood smear themselves. The blood smear should be reviewed if possible, as it may show findings that help to narrow the diagnosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Size</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Small platelets </strong>– Small platelets are characteristic of Wiskott-Aldrich syndrome, ARPC1B deficiency, congenital autosomal recessive small-platelet thrombocytopenia, and PTPRJ-related thrombocytopenia.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Giant platelets </strong>– Giant platelets are often as large as or larger than a normal RBC  (<a class="graphic graphic_picture graphicRef72433" href="/d/graphic/72433.html" rel="external">picture 1</a>). Giant platelets are seen in Bernard-Soulier syndrome, gray platelet syndrome, MYH9-related disease, and Paris-Trousseau syndrome. (See <a class="local">'Specific disorders'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Granules </strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Hypogranulation</strong> – Hypogranulated, pale, or gray platelets can indicate alpha granule deficiency (a feature of Gray platelet syndrome) and alpha-delta storage pool deficiency [<a href="#rid23">23-25</a>]. (See <a class="local">'Gray platelet syndrome'</a> below.)</p><p></p><p class="bulletIndent3">Pale platelets can also be seen in dense granule disorders including Chediak-Higashi syndrome and Hermansky-Pudlak syndrome. (See <a class="local">'Chediak-Higashi syndrome'</a> below and <a class="local">'Hermansky-Pudlak syndrome'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Giant platelet granules</strong> – In Paris-Trousseau syndrome, some platelets may have very large alpha granules. (See <a class="local">'Paris-Trousseau syndrome'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Giant granules in neutrophils</strong> – Some granule biogenesis disorders, including Chediak-Higashi syndrome, can have giant granules in other blood cells such as neutrophils  (<a class="graphic graphic_picture graphicRef71313" href="/d/graphic/71313.html" rel="external">picture 2</a>). (See <a class="local">'Chediak-Higashi syndrome'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Basic metabolic panel, liver function tests, iron studies </strong>– This testing is appropriate if there is concern for possible kidney or liver disease contributing to thrombocytopenia or coagulation abnormalities, or as a syndromic feature of an IPFD. (See <a class="local">'Clinical spectrum (thrombocytopenia, platelet size, syndromic features)'</a> above.)</p><p></p><p class="bulletIndent1">Iron deficiency is common in persons with IPFDs with increased iron losses or needs (from bleeding, menses, or pregnancy), particularly before menopause. Iron studies should be performed if there is any concern about iron deficiency. (See  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Diagnostic evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coagulation testing </strong>– This is appropriate for any concerning bleeding history. It should include prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, and VWD testing (performed sequentially or simultaneously). (See  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder", section on 'Laboratory evaluation'</a>.)</p><p></p><p class="headingAnchor" id="H903793545"><span class="h3">Platelet function testing</span><span class="headingEndMark"> — </span>Appropriate for an individual with a bleeding phenotype or other reason to suspect platelet dysfunction. It is typically reserved until after an evaluation for more common bleeding disorders; it may be used to evaluate bleeding out of proportion to mild abnormalities detected on initial laboratory evaluation  (<a class="graphic graphic_algorithm graphicRef138359" href="/d/graphic/138359.html" rel="external">algorithm 1</a>). (See <a class="local">'CBC, blood smear, coagulation testing'</a> above.)</p><p>Platelet aggregometry is the gold standard test for diagnosing platelet function disorders. Traditional aggregation assays use a panel of platelet agonists to evaluate platelet activation and aggregation in vitro. Either whole blood or platelet-rich plasma is tested depending on the technique. Common agonists used include ADP, arachidonic acid, collagen, epinephrine, a thromboxane A<sub>2</sub> mimetic, and ristocetin. Thrombin or thrombin receptor activating peptides may sometimes be used. Since many common medications can affect platelet function, care must be taken to avoid their use for at least several days prior to testing. (See  <a class="medical medical_review" href="/d/html/4433.html" rel="external">"Platelet function testing", section on 'Platelet aggregometry'</a>.)</p><p>Normal platelet aggregation in response to ADP and epinephrine involves a biphasic response, although the visualization of two waves may require ADP titration. The first wave of aggregation reflects activation of integrin alphaIIbbeta3 and subsequent crosslinking of platelets via fibrinogen binding  (<a class="graphic graphic_figure graphicRef56188" href="/d/graphic/56188.html" rel="external">figure 2</a>). The second wave reflects platelet degranulation and enhanced aggregation due to the release of additional platelet agonists and thromboxane generation. Arachidonic acid, collagen, and thrombin provoke only a single burst of aggregation. Dilution of a strong agonist may result in tracings more typical of a weak agonist. With ristocetin, agglutination occurs before the close platelet contact triggers subsequent aggregation, but these two waves are often fused. De-aggregation is sometimes evident when there is reduced aggregation, particularly with the thromboxane analogue U46619 or reduced aggregation with ADP due to P2Y<sub>12</sub>-related disease.</p><p>Documentation of the drug history (and drug discontinuation when appropriate) is important when testing platelet function; several classes of drugs can interfere with the results. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/d/html/4433.html" rel="external">"Platelet function testing", section on 'Caveats with testing'</a>.)</p><p>Results expected with specific disorders are summarized in the table  (<a class="graphic graphic_table graphicRef69518" href="/d/graphic/69518.html" rel="external">table 2</a>). Findings should be examined for the following patterns:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lack of agglutination (or aggregation) with ristocetin</strong> – Seen in Bernard-Soulier syndrome; the response to other agonists is normal. (See <a class="local">'Bernard-Soulier syndrome'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minimal to absent aggregation to ADP, epinephrine, thrombin, and collagen</strong> – Seen in Glanzmann thrombasthenia; the response to ristocetin is reduced but present, as agglutination occurs without aggregation. (See <a class="local">'Glanzmann thrombasthenia'</a> below.) </p><p></p><p class="bulletIndent1">Similar aggregation impairments occur in the related disorders ITGA2B/ITGB3-related thrombocytopenia (as activating mutations impair alphaIIbbeta3 expression and reduce their copy number on platelets) and leukocyte adhesion deficiency-III (as kindlin-3 defects impair alphaIIbbeta3 function).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impaired aggregation with arachidonic acid but not with thromboxane A2 mimetics (eg, U46619)</strong> – Seen in aspirin-like syndrome. As thromboxane generation augments some other agonist responses, there is typically also reduced aggregation with lower concentrations of collagen, absent secondary aggregation with epinephrine, and sometimes reduced aggregation with ristocetin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impaired aggregation with ADP with extensive de-aggregation</strong> – Seen in P2Y<sub>12</sub>-related disease or in patients taking a P2Y<sub>12</sub> inhibitor. (See  <a class="medical medical_review" href="/d/html/6683.html" rel="external">"Platelet biology and mechanism of anti-platelet drugs", section on 'P2Y12 inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impaired aggregation with arachidonic acid and thromboxane A2 mimetics</strong> – Seen in TBXA2 receptor related disease; can also be seen in other commonly encountered IPFDs without pathogenic variants in the thromboxane A2 receptor [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impaired aggregation with low concentrations of collagen, arachidonic acid, and thromboxane analog U46619</strong> – Seen in persons with commonly encountered IPFDs that impair aggregation and/or cause nonsyndromic dense granule deficiency (which includes familial platelet disorder with predisposition to myeloid malignancy) [<a href="#rid16">16</a>]. Aggregation is more frequently impaired with low concentrations of collagen, arachidonic acid and thromboxane analog U46619, than with other agonists. Secondary aggregation with epinephrine is often absent or impaired. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impaired primary wave of epinephrine aggregation</strong> – Typical of Quebec platelet disorder, with absent secondary aggregation, with or without accompanying impaired aggregation with other agonists such as ADP and collagen [<a href="#rid18">18</a>]. (See <a class="local">'Quebec platelet disorder'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased aggregation with low concentrations of ristocetin</strong> – Seen in platelet-type and type 2B VWD [<a href="#rid18">18</a>]. (See <a class="local">'Platelet-type VWD'</a> below and  <a class="medical medical_review" href="/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease", section on 'Summary of VWD types'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impaired ristocetin-induced platelet aggregation</strong> – Seen in VWD if there is a significant VWF deficiency or a loss of platelet-dependent VWF function. Can also be seen in IPFDs that impair multiple agonist responses, as aggregation follows ristocetin-induced agglutination. (See  <a class="medical medical_review" href="/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease", section on 'Ristocetin-induced platelet aggregation (RIPA)'</a>.)</p><p></p><p>Single abnormalities with a single agonist (except ristocetin) can be a false positive and are not predictive of a bleeding disorder, whereas impaired aggregation with multiple agonists is predictive of a bleeding disorder [<a href="#rid26">26,27</a>]. Isolated aggregation abnormalities with collagen can be a false positive as IPFDs affecting platelet collagen receptors are rare [<a href="#rid18">18</a>].</p><p>Repeat testing to confirm diagnostic findings is a good practice when assessing for IPFDs and to help in excluding false-positive findings.</p><p>If possible, patients undergoing testing for an IPFD should be evaluated for platelet dense granule deficiency, as it has a prevalence similar to VWD, and confirmed dense granule deficiency is highly predictive of a bleeding disorder [<a href="#rid28">28</a>]. In dense granule deficiency, aggregation findings are nondiagnostic in approximately one-half of the cases, and aggregation testing is not an adequate test. Access to testing with electron microscopy may be limited. (See  <a class="medical medical_review" href="/d/html/4433.html" rel="external">"Platelet function testing", section on 'Tests not commonly used'</a>.) </p><p>There are controversies about the use of platelet secretion testing for IPFD diagnosis, including its usefulness if aggregation studies are normal [<a href="#rid29">29,30</a>]. Flow cytometry can be useful if an IPFD associated with glycoprotein deficiency is suspected (Bernard-Soulier syndrome, Glanzmann thrombasthenia); it can also be used to evaluate platelet function if there is thrombocytopenia, and to assess for defects in activation, granule release, or expression of procoagulants [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/4433.html" rel="external">"Platelet function testing", section on 'Other testing if aggregometry is not available'</a>.)</p><p>Point of care tests may be more readily available than aggregometry at some centers  (<a class="graphic graphic_table graphicRef138645" href="/d/graphic/138645.html" rel="external">table 3</a>), but most of these tests were developed for other purposes and do not have an established role in IPFD diagnosis. Closure times measured by the platelet function analyzer (PFA)-100 are abnormal in severe IPFDs, but normal findings do not exclude an IPFD as the test is insensitive to more common IPFDs [<a href="#rid32">32,33</a>]. Flow cytometry is useful for documenting platelet glycoprotein deficiencies (Bernard-Soulier syndrome or Glanzmann thrombasthenia) and can be used to assess platelet activation and procoagulant markers. Test limitations, performance considerations, and caveats are discussed separately. (See  <a class="medical medical_review" href="/d/html/4433.html" rel="external">"Platelet function testing", section on 'Other testing if aggregometry is not available'</a>.)</p><p class="headingAnchor" id="H911893147"><span class="h3">Genetic testing</span><span class="headingEndMark"> — </span>Decisions about genetic testing should be made by the hematologist following a full clinical evaluation and appropriate platelet function testing.</p><p>Genetic testing can be very useful when it reveals a specific pathogenic variant in a platelet function gene and facilitates testing of first-degree relatives of a proband with an IPFD. (See <a class="local">'Implications for first-degree relatives'</a> below.)</p><p>However, genetic testing has many caveats, especially when whole exome sequencing is performed for rare disorders for which the pathogenicity of many gene variants is uncertain. If a gene panel was performed in an individual with a suspected IPFD and did not reveal a pathogenic variant in platelet function genes, consultation with a platelet function disorders expert may help to determine whether relevant genes were omitted. This is especially important when relevant genes have not been fully characterized.</p><p>There may be value in repeating genetic testing or reevaluating the interpretation if a causative gene variant was not identified initially as information about pathogenicity continues to emerge. In a 2014 series of 111 patients with excessive bleeding who underwent genetic testing, approximately 60 percent had a specific genetic variant associated with an IPFD identified [<a href="#rid34">34</a>]. The yield was much lower (9 percent) for a single-center consecutive case cohort study that evaluated cases of commonly encountered IPFDs without a suspected or known cause and with impaired aggregation to multiple agonists and/or nonsyndromic dense granule deficiency [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H20"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis includes other hereditary bleeding disorders as well as acquired causes of platelet dysfunction and thrombocytopenia.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney or liver disease</strong> – Uremia or chronic liver disease (including due to chronic excess alcohol) can cause platelet dysfunction. Like IPFDs, bleeding can be mucocutaneous. Unlike IPFDs, there will be laboratory abnormalities showing abnormal kidney or liver function. Acute alcohol intake (binge-related drinking) is unlikely to cause major changes in platelet function testing. (See  <a class="medical medical_review" href="/d/html/1947.html" rel="external">"Uremic platelet dysfunction"</a> and  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dysproteinemias or MPNs </strong>– Abnormal paraproteins in multiple myeloma or Waldenstrom macroglobulinemia can cause acquired platelet dysfunction. Hyperviscosity or acquired von Willebrand syndrome can also contribute to bleeding. Platelet dysfunction and bleeding can occur in myeloproliferative neoplasms (MPNs), which can also cause acquired von Willebrand syndrome [<a href="#rid35">35-38</a>]. Like IPFDs, there may be thrombocytopenia; unlike IPFDs, there will be non-platelet abnormalities on the CBC, and the platelet dysfunction may respond to treatment of the underlying disorder. (See  <a class="medical medical_review" href="/d/html/6657.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia", section on 'Overview'</a> and  <a class="medical medical_review" href="/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms", section on 'Thrombosis and bleeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced platelet dysfunction or thrombocytopenia</strong> – Numerous drugs inhibit platelet function. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Aspirin</strong> – Irreversibly inhibits cyclooxygenase-1, causing aggregation abnormalities similar to inherited aspirin-like defects.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NSAIDs</strong> – Many nonsteroidal antiinflammatory drugs (NSAIDs) reversibly inhibit cyclooxygenase-1 and cause abnormal platelet aggregation similar to <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>. (See  <a class="medical medical_review" href="/d/html/7989.html" rel="external">"NSAIDs (including aspirin): Pharmacology and mechanism of action"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>P2Y</strong><strong><sub>12</sub></strong><strong> inhibitors</strong> – Impair ADP aggregation responses. (See  <a class="medical medical_review" href="/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'P2Y12 use'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>BTK inhibitors</strong> – Inhibitors of Bruton tyrosine kinase (BTK), used for lymphoid malignancies, can increase bleeding risk due to platelet dysfunction. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SSRIs</strong> – Selective serotonin reuptake inhibitors (SSRIs) are not considered a major cause of platelet dysfunction, although some agents have been reported to interfere with certain aggregometry tests [<a href="#rid39">39-41</a>]. High quality randomized trials have not shown a statistically significant increase in clinical bleeding, although they may not have been adequately powered to detect small increases. (See  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Bleeding'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other inhibitors </strong>– Agents that inhibit integrin alphaIIbbeta3 (previously called GPIIb/IIIa) can induce Glanzmann thrombasthenia-like abnormalities in platelet function. (See  <a class="medical medical_review" href="/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy", section on 'Glycoprotein IIb/IIIa inhibitors'</a> and  <a class="medical medical_review" href="/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Glycoprotein IIb/IIIa inhibitors'</a>.)</p><p></p><p class="bulletIndent1">Like IPFDs, these drugs may cause abnormalities in platelet aggregometry testing. Additionally, drugs that inhibit platelet function may worsen or unmask an IPFD. Drug-induced platelet dysfunction should be suspected when a patient develops symptoms after a drug is started, irrespective of the indication for the drug. Unlike IPFDs, drug-induced platelet dysfunction resolves upon drug discontinuation (although the prescriber should be consulted before drug discontinuation, unless there is significant bleeding).</p><p></p><p class="bulletIndent1">Numerous other medications can cause thrombocytopenia without altering platelet function, either by an immune-mediated mechanism, direct bone marrow toxicity, or other mechanisms. Unlike IPFDs, the thrombocytopenia will resolve upon drug discontinuation (although the prescriber should be consulted before drug discontinuation, unless there is significant bleeding). (See  <a class="medical medical_review" href="/d/html/6674.html" rel="external">"Drug-induced immune thrombocytopenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other hereditary bleeding disorders</strong> – Mild forms of some factor deficiencies or VWD can have normal initial laboratory testing. Other clotting factor deficiencies and vascular disorders are not always apparent from initial testing. Like IPFDs, these disorders are present from birth, and there may be positive family history. Unlike IPFDs, these disorders have other diagnostic testing and show normal platelet function on platelet function testing. (See  <a class="medical medical_review" href="/d/html/5936.html" rel="external">"Approach to the child with bleeding symptoms", section on 'Normal initial testing'</a> and  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder", section on 'Positive bleeding history and normal initial testing'</a>.)</p><p></p><p class="headingAnchor" id="H35"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H2197418103"><span class="h2">Counseling and communication</span><span class="headingEndMark"> — </span>Individuals with IPFDs should be offered the opportunity to learn about and understand their specific disorder. When possible, referral to a service with relevant expertise, such as a hemophilia treatment center, is appropriate to evaluate and treat an IPFD. </p><p>The patient should be aware of the following general guidance [<a href="#rid19">19</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Drugs and medications to avoid, such as anti-platelet drugs, unless there is an important indication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Planning is needed to treat and prevent bleeding from hemostatic challenges.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For some IPFDs with significant bleeding, avoidance of contact sports may be appropriate. These decisions are made on a case-by-case basis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Good dental hygiene is important to limit the need for future dental procedures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Routine cancer screening should be done according to clinical care guidelines so that problems can be identified early.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Related health issues requiring consideration include iron deficiency and health risks from syndromic features of some IPFDs. (See <a class="local">'Iron deficiency'</a> below and <a class="local">'Other treatments'</a> below.)</p><p></p><p>Individuals with IPFDs should notify any clinician caring for them about their disorder, especially surgeons, obstetricians, dentists, and others performing procedures. Patients can be provided with a wallet card or letter that explains their condition and recommended treatments. Registration with national databases where available can be extremely helpful to ensure all treating clinicians are aware of the bleeding disorder, specific findings, and appropriate treatment(s). </p><p class="headingAnchor" id="H1608228892"><span class="h2">Major bleeding or major surgery</span><span class="headingEndMark"> — </span>Major bleeding in individuals with IPFDs is often triggered by invasive surgical or dental procedures or trauma. All management should be carried out in close collaboration and consultation with the specialized clinic, hemophilia treatment center, or a hemostasis expert [<a href="#rid42">42</a>]. Most treatments of IPFD do not require laboratory monitoring. </p><p>Available treatments for preventing and treating acute bleeding in IPFDs include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Desmopressin</strong> – <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">Desmopressin</a> (DDAVP) is the most commonly used treatment; it is used for many IPFDs. (See <a class="local">'Desmopressin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet transfusions</strong> – Platelet transfusions are used for bleeding that is not adequately controlled by medical therapies, particularly for severe IPFDs or platelet dysfunction unlikely to be corrected by medications, such as Scott syndrome. Carry risks of transfusion reactions and alloimmunization, including the development of platelet antibodies that may limit future responses. (See <a class="local">'Platelet transfusion'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recombinant factor VIIa (rFVIIa)</strong> – rFVIIa is effective for some IPFDs; it carries risks of thrombosis, and cost is high. (See <a class="local">'Recombinant factor VIIa'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antifibrinolytic agents </strong>– Antifibrinolytic agents such as <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> are effective for heavy menstrual bleeding and epistaxis. They are increasingly considered as adjunctive treatment, given the growing evidence they reduce blood loss with cardiac surgery, major orthopedic surgery, severe trauma, and postpartum hemorrhage. Antifibrinolytic therapy is the treatment of choice for bleeding and bleeding prophylaxis in Quebec platelet disorder. (See <a class="local">'Antifibrinolytic agents'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local therapies</strong> – Local therapies may also be used when bleeding sites are accessible. (See <a class="local">'Local therapies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TPO-RAs</strong> – Short-term thrombopoietin receptor agonist (TPO-RA) therapy has been used for temporary improvement of the platelet count in some IPFDs with significant thrombocytopenia when there is sufficient time for advance planning [<a href="#rid19">19,43</a>]. (See <a class="local">'Other treatments'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatments for heavy menstrual bleeding</strong> – Treatments for heavy menstrual bleeding in IPFDs are similar to that of other bleeding disorders. (See  <a class="medical medical_review" href="/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management"</a>.)</p><p></p><p class="headingAnchor" id="H3304025684"><span class="h3">Platelet transfusion</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and mechanism</strong> – Platelet transfusions should be considered for serious bleeding and major surgery in patients with more severe IPFDs (such as Scott syndrome), and when other treatments such as DDAVP do not adequately control bleeding [<a href="#rid19">19,42,44</a>]. For less-severe IPFDs and less-severe bleeding, medical therapies can be used to avoid the risk of platelet alloimmunization and other complications of platelet transfusion including platelet refractoriness and transfusion reactions. (See <a class="local">'Conceptual framework'</a> above.)</p><p></p><p class="bulletIndent1">Platelet transfusions are often not necessary for managing less severe IPFDs, as patients with commonly encountered IPFDs report bleeding mainly for hemostatic challenges done without prophylactic medications to reduce bleeding [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1">Recombinant factor VIIa (rFVIIa) has been used to treat and prevent bleeding, and to spare platelet transfusions, mainly in severe IPFDs with significant risks for forming platelet antibodies, as discussed below [<a href="#rid45">45</a>]. (See <a class="local">'Recombinant factor VIIa'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and irradiation</strong> – The number of transfusions required depends on the severity of bleeding, degree of platelet dysfunction, and platelet count. Dosing and the duration of platelet transfusion support requires clinical judgement, particularly for IPFDs without thrombocytopenia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Typically, one apheresis unit or six units of whole blood derived platelets are transfused, with clinical assessment and repeat platelet count to determine if more transfusions are needed. (See  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'Ordering platelets'</a>.)</p><p></p><p class="bulletIndent3">For IPFDs that impair aggregation or activation but not initial platelet adhesion (eg, Glanzmann thrombasthenia and RASGRP2-related disease [also called platelet-type bleeding disorder-18]), animal models suggest there is in vivo competition between transfused platelets and the patient's dysfunctional platelets [<a href="#rid46">46</a>]; dosing needs for those disorders may be fourfold greater. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If there is massive bleeding requiring massive transfusion, platelets, plasma, and red blood cells are typically transfused in a 1:1:1 ratio. (See  <a class="medical medical_review" href="/d/html/7931.html" rel="external">"Massive blood transfusion", section on 'Component ratio (1:1:1)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Irradiation</strong> – Irradiated blood products (including platelets) must be used for <strong>all </strong>patients at risk for transfusion-associated graft-versus-host disease (TA-GVHD) [<a href="#rid47">47</a>]. This includes IPFDs associated with immunodeficiency, including:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>ARPC1B deficiency</p><p class="bulletIndent3"><span class="glyph">-</span>Chediak-Higashi syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>Hermansky-Pudlak syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>Stormorken syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>Wiskott-Aldrich syndrome/X-linked thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>Wiskott-Aldrich syndrome 2</p><p></p><p class="bulletIndent2">Leukoreduction is <strong>not</strong> sufficient to prevent TA-GVHD. Some pathogen inactivation process may be effective, although supporting data are less extensive. (See  <a class="medical medical_review" href="/d/html/7928.html" rel="external">"Transfusion-associated graft-versus-host disease", section on 'Prevention'</a> and  <a class="medical medical_review" href="/d/html/7929.html" rel="external">"Pathogen inactivation of blood products", section on 'Preventing transfusion-associated graft-versus-host disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence for efficacy </strong>– Most evidence for platelet transfusion comes from clinical experience; many IPFDs are too rare to study systematically, and more evidence for efficacy is needed. Among IPFDs, more evidence for effectiveness of platelet transfusion is available for the thrombocytopenic disorders [<a href="#rid46">46</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute transfusion reactions</strong> – Platelet transfusions carry risks of acute transfusion reactions (allergic, immunologic, transfusion-associated circulatory overload, transfusion-related acute lung injury, transfusion-transmitted bacterial infection). (See  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'Complications'</a> and  <a class="medical medical_review" href="/d/html/95132.html" rel="external">"Approach to the patient with a suspected acute transfusion reaction"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunodeficiency and TA-GVHD</strong> – Transfusion-associated graft-versus-host disease (TA-GVHD) is a life-threatening transfusion reaction with an extremely high mortality rate (almost always fatal) [<a href="#rid47">47</a>]. In TA-GVHD, lymphocytes in the transfused product attack the recipient's immune system, including skin, gut, and bone marrow, resulting in bone marrow aplasia within 4 to 30 days after transfusion. (See  <a class="medical medical_review" href="/d/html/7928.html" rel="external">"Transfusion-associated graft-versus-host disease"</a>.)</p><p></p><p class="bulletIndent2">IPFDs associated with immunodeficiency can be considered risk factors for TA-GVHD and an indication for irradiated blood products (or in some cases, leukoreduced blood products. (See  <a class="medical medical_review" href="/d/html/7928.html" rel="external">"Transfusion-associated graft-versus-host disease", section on 'Immunodeficiency'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alloimmunization and refractoriness to platelet transfusion</strong> – The risk of alloimmunization against platelet glycoproteins or HLA antigens in specific IPFDs is challenging to determine. It is most likely in disorders requiring repeated transfusions and with deficiency of a major platelet glycoprotein, such as Glanzmann thrombasthenia and Bernard-Soulier syndrome. Alloimmunization can lead to refractoriness to platelet transfusion and reduced efficacy of platelet transfusions; during pregnancy this can also pose risks to the fetus. (See  <a class="medical medical_review" href="/d/html/7922.html" rel="external">"Refractoriness to platelet transfusion"</a>.)</p><p></p><p class="headingAnchor" id="H692958526"><span class="h3">Recombinant factor VIIa</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and mechanism</strong> – Recombinant activated factor VII (rFVIIa) is a "bypassing therapy" originally developed for hemophilia that can promote clotting by activating a later step in the coagulation cascade. It is thought to promote thrombin generation at sites of vascular damage in patients with IPFDs [<a href="#rid48">48-52</a>]. (See  <a class="medical medical_review" href="/d/html/1341.html" rel="external">"Recombinant factor VIIa: Administration and adverse effects", section on 'Background and mechanism of action'</a>.) </p><p></p><p class="bulletIndent1">Treatment with rFVIIa is especially appealing in individuals who are at risk for developing alloantibodies to platelet antigens, including anti-HLA, anti-alphaIIbbeta3 in Glanzmann thrombasthenia, or anti-GP Ib/IX/V in Bernard-Soulier syndrome. Bleeding in patients with several severe IPFDs has been successfully treated with rFVIIa, and the rFVIIa product NovoSeven is approved for Glanzmann thrombasthenia. (See  <a class="medical medical_review" href="/d/html/1341.html" rel="external">"Recombinant factor VIIa: Administration and adverse effects", section on 'Glanzmann thrombasthenia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and efficacy</strong> – A 2021 review of rFVIIa use in patients with Glanzmann thrombasthenia identified 333 instances of administration for bleeding and 157 for surgical procedures [<a href="#rid45">45</a>]. Overall efficacy was 79 percent for bleeding and 88 percent for surgery; it was effective in individuals with or without anti-platelet alloantibodies. Dosing was variable (range, 28 to 450 mcg/kg; median, 90 mcg/kg); most individuals received from one to three doses per admission. Therapy was well-tolerated, with only one episode of deep vein thrombosis (DVT) among all the reports.</p><p></p><p class="bulletIndent1">Smaller series have also described rFVIIa use in Bernard-Soulier syndrome, typically in combination with platelet transfusions [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1">Rare descriptions of other schedules and preventive therapy have been reported, including weekly low-dose rFVIIa for a patient with Glanzmann thrombasthenia and refractory bleeding [<a href="#rid54">54,55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Possible benefits of rFVIIa must be balanced against the risk of thrombosis and the cost. Further details of the dosing and thromboembolic risk are discussed separately. (See  <a class="medical medical_review" href="/d/html/1341.html" rel="external">"Recombinant factor VIIa: Administration and adverse effects", section on 'Thromboembolic complications'</a>.)</p><p></p><p class="headingAnchor" id="H189421729"><span class="h2">Minor bleeding or minor procedures</span><span class="headingEndMark"> — </span>Management should be carried out in close collaboration and consultation with an expert service, such as a hemophilia treatment center [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H1385365146"><span class="h3">Local therapies</span><span class="headingEndMark"> — </span>Local therapies may be particularly effective for bleeding from sites that can be easily accessed, such as [<a href="#rid19">19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epistaxis</strong> – Nasal packing and/or endoscopic cauterization can be used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dental extractions</strong> – <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">Tranexamic acid</a> can be applied as mouthwash or soaked gauze (after dissolving tranexamic acid tablets in water) [<a href="#rid19">19</a>]. (See <a class="local">'Antifibrinolytic agents'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heavy menstrual bleeding</strong> – Evaluate for anatomic causes of bleeding such as polyps or uterine fibroids that could be treated locally. Endometrial ablation can be used if future pregnancies are not desired. (See  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Superficial wounds</strong> – Topical <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> can be administered on gelatin sponges or gauzes [<a href="#rid19">19</a>]. (See <a class="local">'Antifibrinolytic agents'</a> below.)</p><p></p><p class="headingAnchor" id="H36"><span class="h3">Desmopressin</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">Desmopressin</a> (1-deamino-8-D-arginine vasopressin, DDAVP) is commonly used to treat or prevent bleeding in less severe IPFDs. There is considerable experience with using DDAVP to treat minor bleeding in individuals with von Willebrand disease (VWD), where it leads to release of endogenous VWF from platelets and endothelial cells [<a href="#rid56">56,57</a>]. DDAVP also increases plasma VWF and factor VIII levels in individuals with IPFDs [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/d/html/122618.html" rel="external">"von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care", section on 'DDAVP'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing </strong>– DDAVP can be given subcutaneously, intranasally, or intravenously. A DDAVP trial is not performed for individuals with IPFDs, as the only relevant endpoint is reduction in bleeding or prevention of challenge-related bleeding. Dosing is similar to dosing for VWD. (See  <a class="medical medical_review" href="/d/html/122618.html" rel="external">"von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care", section on 'DDAVP'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Tachyphylaxis and hyponatremia can occur. Instructions and orders for fluid restriction (maximum intake of 1 to 1.5 liters of free water during the 24 hours after DDAVP) are important to limit the risks for water intoxication, as potent fluid retention lasts for 12 to 24 hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence for efficacy</strong> – Efficacy of DDAVP to prevent bleeding after dental extraction and minor surgery has been reported in mild IPFDs [<a href="#rid42">42,59,60</a>]. In vitro studies suggest DDAVP improves platelet procoagulant function in IPFDs without altering platelet activation, adhesive, or aggregation function [<a href="#rid1">1</a>]. </p><p></p><p class="headingAnchor" id="H39"><span class="h3">Antifibrinolytic agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – An antifibrinolytic agent (<a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> or epsilon <a class="drug drug_general" data-topicid="8561" href="/d/drug information/8561.html" rel="external">aminocaproic acid</a>) may be helpful in reducing bleeding, especially if bleeding is mucosal, such as with:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dental extractions [<a href="#rid42">42</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Epistaxis</p><p class="bulletIndent2"><span class="glyph">•</span>Heavy menstrual bleeding</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">Tranexamic acid</a> is more commonly used in patients without bleeding disorders to reduce surgical, traumatic, or postpartum hemorrhage. It is the treatment of choice for bleeding and bleeding prophylaxis in Quebec platelet disorder. (See <a class="local">'Quebec platelet disorder'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – Typical <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> dosing for IPFDs is similar to other bleeding disorders and non-bleeding disorder uses (with adjustments if kidney function is impaired). (See  <a class="medical medical_review" href="/d/html/122618.html" rel="external">"von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care", section on 'Antifibrinolytic agents'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">Tranexamic acid</a>, 25 mg/kg per dose orally every six to eight hours or 10 mg/kg intravenously three times per day.</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8561" href="/d/drug information/8561.html" rel="external">Aminocaproic acid</a>, 25 to 50 mg/kg per dose orally (maximum 5 g dose) four times per day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration</strong> – The duration of antifibrinolytic therapy is uncertain. Treatment can be provided on the day of surgery, trauma, or postpartum hemorrhage and extended if bleeding continues. An antifibrinolytic agent can be combined with other therapies and is generally well-tolerated. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Short-term use of these agents, or their use for treatment of heavy menstrual bleeding, is not associated with an increase in the risk of thrombosis [<a href="#rid61">61</a>]. However, thrombosis has occurred in individuals with Quebec platelet disorder during periods of high risk for thrombosis due to atrial fibrillation, or when fibrinolytic inhibitor therapy was necessary to treat bleeding during a period of high thrombotic risk [<a href="#rid21">21,62</a>]. Combined antifibrinolytic and anticoagulant therapy has been tried to mitigate these risks for persons with Quebec platelet disorder [<a href="#rid62">62,63</a>]. <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">Tranexamic acid</a> treatment leads to increased platelet counts in Quebec platelet disorder, suggesting the underlying fibrinolytic defect is responsible for the lower platelet counts of affected individuals.</p><p></p><p class="headingAnchor" id="H2225637757"><span class="h2">Other treatments</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hormonal contraceptives</strong> – Suppression of menses or use of hormonal contraception methods, including medicated intrauterine devices, may reduce menstrual blood loss in IPFD. (See  <a class="medical medical_review" href="/d/html/5423.html" rel="external">"Hormonal contraception for menstrual suppression"</a> and  <a class="medical medical_review" href="/d/html/139017.html" rel="external">"von Willebrand disease (VWD): Gynecologic and obstetric considerations", section on 'Interventions for HMB'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TPO-RAs</strong> – A thrombopoietin receptor agonist (TPO-RA; such as <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> or <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a>) may temporarily increase platelet counts. TPO-RAs have been used in several thrombocytopenic IPFDs including MYH9-related disease, Wiskott-Aldrich syndrome/X-linked thrombocytopenia, Bernard-Soulier syndrome, and ANKRD26-related thrombocytopenia [<a href="#rid19">19,43</a>]. A TPO-RA would only be expected to raise the platelet count, not to correct the underlying platelet dysfunction.</p><p></p><p class="bulletIndent1">Small studies of chronic TPO-RA use in IPFDs have reported good efficacy in increasing the platelet count without significant safety concerns [<a href="#rid64">64-67</a>]. As an example, in a study involving 12 patients with MYH9-related disease and platelet counts &lt;50,000/microL, <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> increased platelet counts to ≥100,000/microL or three times baseline in 8 of the 12 and reduced bleeding in 8 of 10 with bleeding symptoms at baseline [<a href="#rid68">68</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematopoietic stem cell transplant</strong> <strong>and gene therapy</strong> – Individuals with some severe forms of IPFDs who have frequent major bleeding episodes may be treated with more aggressive (and potentially curative) therapy, such as allogeneic hematopoietic stem cell transplantation (HSCT). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Allogeneic HSCT has been used for Glanzmann thrombasthenia. (See <a class="local">'Glanzmann thrombasthenia'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HSCT is an important treatment for congenital amegakaryocytic thrombocytopenia (CAMT) as it evolves to bone marrow failure. HSCT may be warranted for malignant progression of familial platelet disorder with germline predisposition to hematological malignancy; if the donor is related, they must test negative for the causative germline gene variant(s) [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Allogeneic HSCT is also appropriate treatment for syndromic conditions in which other hematologic complications can be life-threatening. Examples include Chediak-Higashi syndrome and Wiskott-Aldrich syndrome. In Wiskott-Aldrich syndrome, outcomes are better for children transplanted before five years of age [<a href="#rid70">70</a>]. (See <a class="local">'Chediak-Higashi syndrome'</a> below and <a class="local">'Wiskott-Aldrich syndrome'</a> below.)</p><p></p><p class="bulletIndent1">Single gene disorders are also potentially amenable to autologous HSCT using gene therapy to restore normal gene function to autologous hematopoietic stem cells, but this has not yet been studied in most IPFDs, with the exception of Wiskott-Aldrich syndrome. (See  <a class="medical medical_review" href="/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing", section on 'Inherited single gene disorders'</a> and  <a class="medical medical_review" href="/d/html/3953.html" rel="external">"Wiskott-Aldrich syndrome", section on 'Gene therapy'</a>.)</p><p></p><p class="headingAnchor" id="H81577237"><span class="h2">Obstetric considerations</span><span class="headingEndMark"> — </span>Pregnancy should be managed in close collaboration with a hemophilia treatment center or hemostasis expert [<a href="#rid42">42</a>]. This should include discussions about options for avoiding an IPFD in offspring (if the disorder is severe), screening for and treatment of iron deficiency, and management of pregnancy and delivery (including pain control if neuraxial anesthesia will not be used). Ideally, the hemophilia treatment center should become familiar with the patient prior to conception or early in the pregnancy to allow a close review of the patient's case and to help plan treatment during the pregnancy. (See  <a class="medical medical_review" href="/d/html/115637.html" rel="external">"Anemia in pregnancy", section on 'Iron deficiency'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risks</strong> – Childbirth poses bleeding risks for individuals with IPFDs; rates of excessive bleeding with delivery have been as high as 40 to 50 percent for some IPFDs [<a href="#rid71">71,72</a>]. One study found that individuals with commonly encountered IPFDs (that manifest with aggregation defects and/or dense granule deficiency) have increased risks for excessive bleeding with childbirth/miscarriage (odds ratio [OR] 17) and prolonged menses (OR 7) [<a href="#rid16">16</a>]. Compared with unaffected relatives, individuals with Quebec platelet disorder also have increased risks for bleeding with childbirth (OR 12) and prolonged menses (OR 14) [<a href="#rid21">21</a>]. These increased risks largely reflect bleeding with bleeding challenges in untreated individuals.</p><p></p><p class="bulletIndent1">Another risk in some disorders is that maternal anti-platelet antibodies could cross the placenta and cause fetal or neonatal alloimmune thrombocytopenia (NAIT). Maternal antibodies may be induced by prior transfusions or transplacental hemorrhage with sensitization to fetal platelet antigens, and the likelihood of NAIT increases if existing anti-platelet antibodies are increased by an anamnestic response [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/6804.html" rel="external">"Fetal and neonatal alloimmune thrombocytopenia: Parental evaluation and pregnancy management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Likelihood of IPFD in offspring</strong> – Some IPFDs are autosomal dominant, meaning offspring have a 50 percent chance of inheriting the gene variant associated with disease and a 50 percent chance of being unaffected. </p><p></p><p class="bulletIndent1">For autosomal recessive conditions, if the parents are both heterozygous carriers and have had an affected child, the chance of having another affected child is 25 percent for each pregnancy. The risks for rare autosomal recessive IPFDs are higher in kindreds with consanguinity.</p><p></p><p class="bulletIndent1">Individuals with IPFDs, including those who do not have a known gene variant associated with their IPFD, should be offered the opportunity to speak with an expert in IPFDs or to have genetic testing and counseling prior to attempted conception. (See  <a class="medical medical_review" href="/d/html/103304.html" rel="external">"Genetic counseling: Family history interpretation and risk assessment", section on 'Resources for genetic counseling'</a>.)</p><p></p><p class="bulletIndent1">Reproductive options to avoid having an affected offspring are rarely needed; these include preimplantation genetic testing (PGT) of embryos conceived by in vitro fertilization (IVF), use of donor gametes (donor sperm or donor egg), or adoption. (See  <a class="medical medical_review" href="/d/html/6783.html" rel="external">"Preimplantation genetic testing"</a> and  <a class="medical medical_review" href="/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions"</a> and  <a class="medical medical_review" href="/d/html/7423.html" rel="external">"Donor insemination"</a> and  <a class="medical medical_review" href="/d/html/2854.html" rel="external">"Adoption"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preconception</strong> – Prior to conception, individuals with IPFDs should have the opportunity to discuss maternal and fetal risks and approaches to minimizing these risks. Preimplantation genetic testing of embryos is a consideration for some monogenic disorders, but use has not been reported for IPFDs. (See  <a class="medical medical_review" href="/d/html/6783.html" rel="external">"Preimplantation genetic testing"</a> and  <a class="medical medical_review" href="/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions"</a> and  <a class="medical medical_review" href="/d/html/7423.html" rel="external">"Donor insemination"</a>.)</p><p></p><p class="bulletIndent1">Screening for (and treating) iron deficiency is especially important for individuals with IPFDs during early pregnancy. (See  <a class="medical medical_review" href="/d/html/115637.html" rel="external">"Anemia in pregnancy", section on 'How to screen for iron deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy</strong> – Bleeding during pregnancy in IPFDs is rare, unlike bleeding with delivery and postpartum. Management and planning for delivery should involve the hemophilia treatment center and a high-risk obstetrician.</p><p></p><p class="bulletIndent1">Data on the safety of TPO-RAs during the third trimester to increase the platelet count prior to delivery are very limited, with a small series describing their use for individuals with immune thrombocytopenia and one individual with MYH9-related disease [<a href="#rid19">19</a>]. (See <a class="local">'Other treatments'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delivery and postpartum</strong> – The risk of maternal hemorrhage is greatest at the time of delivery and postpartum [<a href="#rid71">71,72</a>]. Postpartum hemorrhage can occur up to one to two weeks following delivery, and individuals with IPFDs may have very prolonged postpartum bleeding. Treatment is individualized.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vaginal delivery</strong> – For vaginal delivery, some experts treat with <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (DDAVP), and for more severe IPFDs, rFVIIa and <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> at the time of delivery, as a way to improve hemostasis and avoid platelet transfusions. (See <a class="local">'Recombinant factor VIIa'</a> above and <a class="local">'Antifibrinolytic agents'</a> above.) </p><p></p><p class="bulletIndent2">The use of DDAVP during pregnancy and childbirth requires clinical judgement as there are no randomized trials on the effectiveness and safety.</p><p></p><p class="bulletIndent2">If there is thrombocytopenia, the target minimum platelet count is often &gt;50,000/microL for a surgical or interventional delivery. This may be accomplished by administration of HLA-matched platelet transfusion (to reduce alloimmunization), or with <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> to further reduce bleeding risk. (See <a class="local">'Platelet transfusion'</a> above and <a class="local">'Antifibrinolytic agents'</a> above.)</p><p></p><p class="bulletIndent2">If the fetus is diagnosed with or at risk for an IPFD or there is concern for NAIT, forceps should not be used [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cesarean delivery</strong> – Cesarean delivery is treated as a major surgical procedure. For severe IPFDs, HLA-selected platelets and <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> are recommended. For thrombocytopenic IPFD, the optimal platelet count is generally determined by the obstetric team and hematologists taking care of the patient.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anesthesia</strong> – Neuraxial anesthesia is generally not used in individuals with mild or severe IPFDs due to concerns about spinal epidural hematoma and uncertainties about sustained, adequate hemostatic correction. Some reviews state that neuraxial anesthesia is contraindicated (for Glanzmann thrombasthenia), although there are limited case reports describing platelet transfusion to cover neuraxial anesthesia (eg, for MYH9-related disease) [<a href="#rid71">71,72</a>]. A plan for labor anesthesia should be discussed prior to labor, and options for pain relief should also be planned and discussed. (See  <a class="medical medical_review" href="/d/html/4469.html" rel="external">"Adverse effects of neuraxial analgesia and anesthesia for obstetrics", section on 'Neuraxial analgesia and low platelets'</a>.) </p><p></p><p class="headingAnchor" id="H2425596156"><span class="h2">Iron deficiency</span><span class="headingEndMark"> — </span>Individuals with pregnancies or who have severe and/or frequent bleeding (epistaxis, heavy menstrual bleeding) are at greater risk of developing iron deficiency. </p><p>Periodic screening with ferritin is appropriate, with iron replacement (oral or parenteral iron) as required to treat iron deficiency anemia as well as iron deficiency without anemia, which may be symptomatic, and to improve iron stores before surgery, pregnancy, or delivery. The frequency of screening and the route of iron administration are individualized. (See  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Diagnostic evaluation'</a>.)</p><p class="headingAnchor" id="H86355382"><span class="h2">Implications for first-degree relatives</span><span class="headingEndMark"> — </span>First-degree relatives should have the option to be evaluated, starting with a thorough bleeding history. (See <a class="local">'History and examination'</a> above.)</p><p>Relatives with a positive bleeding history and a known family history of an IPFD should undergo testing for that disorder. For some disorders, testing of umbilical cord blood had been used to identify infants at high risk of an IPFD (eg, a child of a parent with Quebec platelet disorder).</p><p>For mild disorders, testing may be delayed until older school age, since the volume of blood needed for platelet function testing can be large (approximately 40 mL), and this allows the child to be involved in decision-making around testing. These decisions are made on a case-by-case basis depending on the child's bleeding symptoms and need for surgical procedures or dental extractions.</p><p class="headingAnchor" id="H3109064102"><span class="h1">SPECIFIC DISORDERS</span><span class="headingEndMark"> — </span>IPFDs include many rare conditions [<a href="#rid42">42,73-75</a>]. Selected disorders are described below. </p><p>Some of these disorders affect platelet count, some affect platelet size, and some are associated with syndromic features that may be more clinically impactful than the platelet dysfunction. (See <a class="local">'Clinical spectrum (thrombocytopenia, platelet size, syndromic features)'</a> above.) </p><p class="headingAnchor" id="H882823312"><span class="h2">With thrombocyopenia</span></p><p class="headingAnchor" id="H3893747293"><span class="h3">Bernard-Soulier syndrome</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathophysiology</strong> – Bernard-Soulier syndrome (BSS) is caused by pathogenic variants in <em>GP9, GP1BA, </em>or <em>GP1BB</em> [<a href="#rid76">76,77</a>]. These genes encode components of the GPIb/IX complex, which serves as one of the platelet receptors for von Willebrand factor (VWF). BSS platelets have reduced adherence to VWF at sites of vascular injury (but they can still adhere via integrin alphaIIbbeta3).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and inheritance</strong> – The prevalence is approximately 1 in 1 million. Transmission is usually autosomal recessive, but autosomal dominant forms also exist.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and evaluation</strong> – BSS generally presents with a bleeding phenotype with mild to moderate thrombocytopenia and large platelets. The bleeding phenotype is highly variable from mild to severe [<a href="#rid78">78</a>]. There are no other syndromic features. The diagnosis can be made by platelet aggregometry. BSS platelets do not agglutinate or aggregate in response to ristocetin  (<a class="graphic graphic_table graphicRef69518" href="/d/graphic/69518.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Other than standard management discussed above, there are no BSS-specific recommendations. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H1767965201"><span class="h3">Gray platelet syndrome</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathophysiology</strong> – Gray platelet syndrome (a form of alpha granule deficiency) is caused by pathogenic variants in <em>NBEAL2</em>, which encodes a protein important in alpha granule biogenesis [<a href="#rid79">79</a>]. Pathogenic variants in<em> GFI1B </em>have also been described to cause gray platelet syndrome. <em>GFI1B</em> encodes a transcriptional repressor active in megakaryocytes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and inheritance</strong> – Gray platelet syndrome is very rare. Transmission is autosomal recessive for the <em>NBEAL2</em>-related form and autosomal dominant for the <em>GFI1B</em>-related form [<a href="#rid24">24,79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and evaluation</strong> – Gray platelet syndrome generally presents with progressive thrombocytopenia, myelofibrosis, splenomegaly, and elevated vitamin B12 levels [<a href="#rid24">24</a>]. Platelets are pale and lack azurophilic granules. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Standard management is discussed above. (See <a class="local">'Treatment'</a> above.) </p><p></p><p class="headingAnchor" id="H367884237"><span class="h3">GPVI deficiency</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathophysiology</strong> – Glycoprotein (GPVI) deficiency is caused by pathogenic variants in <em>GP6,</em> which encodes a platelet collagen receptor [<a href="#rid80">80</a>]. (See <a class="local">'Mechanisms and gene variants'</a> above and  <a class="medical medical_review" href="/d/html/6683.html" rel="external">"Platelet biology and mechanism of anti-platelet drugs", section on 'Collagen receptors (GPIa/IIa and GPVI)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and inheritance</strong> – GPVI deficiency is very rare. Transmission is autosomal recessive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and evaluation</strong> – Platelet counts are variable, from severe thrombocytopenia to normal platelet count. Some individuals have had autoimmune manifestations, but the disorder is too rare to determine whether these are causally related or incidental findings [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Standard bleed management is discussed above. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H1733268835"><span class="h3">MYH9-related disease</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathophysiology</strong> – MYH9-related disease is caused by pathogenic variants in <em>MYH9</em>, which encodes a heavy chain of non-muscle myosin. Before the responsible gene was identified, several separate syndromes were described, including May-Hegglin anomaly, Fechtner syndrome, Epstein syndrome, Sebastian syndrome, and others, but these are now considered to be the same disorder. The bleeding history can be minimal or significant. MYH9 is an intracellular protein in non-muscle cells that binds to actin and helps regulate changes in cell shape, adhesion, membrane protrusion, and migration [<a href="#rid81">81</a>]. Thrombocytopenia is thought to be due to reduced megakaryopoiesis, and platelet dysfunction may arise from abnormalities in activation [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and inheritance</strong> – The prevalence is unknown; it has been estimated to be as high as 1 in 25,000, although only a few hundred kindreds have been described [<a href="#rid82">82</a>]. Transmission is autosomal dominant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and evaluation </strong>– Clinical features include thrombocytopenia (platelet count varies by kindred), large platelets, and Döhle body-like inclusions in neutrophils. Different gene variants have different manifestations in other organs (sensorineural hearing loss, glomerulonephritis, cataracts) [<a href="#rid42">42,81,83,84</a>]. Aggregation findings are typically normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Standard management is discussed above. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1">One report described improvement in platelet counts with a thrombopoietin receptor agonist (TPO-RA) in a small number of patients with baseline platelet counts &lt;50,000/microL and significant bleeding; bleeding was also reduced [<a href="#rid68">68</a>]. The need for other interventions depends on the bleeding history and other disease manifestations. (See <a class="local">'Other treatments'</a> above.)</p><p></p><p class="headingAnchor" id="H2676375834"><span class="h3">Paris-Trousseau syndrome</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathophysiology</strong> – Paris-Trousseau syndrome is caused by pathogenic variants in <em>FLI1</em>, which encodes a transcription factor important in hematopoietic cells.</p><p></p><p class="bulletIndent1">Jacobsen syndrome is a very rare chromosomal microdeletion syndrome that deletes <em>FLI1</em> and other genes in the same chromosomal region. (See  <a class="medical medical_review" href="/d/html/16660.html" rel="external">"Microdeletion syndromes (chromosomes 1 to 11)", section on '11q24.1 deletion syndrome (Jacobsen syndrome)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and inheritance</strong> – The prevalence is unknown. Transmission is autosomal dominant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and evaluation</strong> – Clinical features include mild to moderate thrombocytopenia and large platelets, some of which may show abnormally large alpha granules. Other syndromic features may include intellectual disability; dysmorphic craniofacial features; and congenital anomalies affecting the heart, kidneys, and gastrointestinal tract. (See  <a class="medical medical_review" href="/d/html/5921.html" rel="external">"Causes of thrombocytopenia in children", section on 'Large or giant platelets'</a> and  <a class="medical medical_review" href="/d/html/16660.html" rel="external">"Microdeletion syndromes (chromosomes 1 to 11)", section on '11q24.1 deletion syndrome (Jacobsen syndrome)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Standard bleed management is discussed above. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1">Management of syndromic features depends on the specific findings; multidisciplinary input is required.</p><p></p><p class="headingAnchor" id="H4201094772"><span class="h3">Platelet-type VWD</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathophysiology </strong>– Platelet-type von Willebrand disease (VWD) is caused by gain-of-function mutations in the <em>GP1BA g</em>ene, which encodes a component of the GPIb/IX/V complex, a receptor for VWF. These variants cause increased binding of VWF to platelets and rapid clearance of the GPIb/IX/V-VWF complex, leading to thrombocytopenia and low VWF activity [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and inheritance</strong> – The prevalence is unknown. The disorder is autosomal dominant, but fewer than 100 cases are reported worldwide, and there is significant potential for misdiagnosis as other conditions [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and evaluation</strong> – Clinical features are similar to other IPFDs. Features that should raise suspicion of this disorder include reduced VWF activity, a low ratio of VWF activity to VWF antigen, loss of high molecular weight VWF multimers, and increased aggregation with low concentrations of ristocetin [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease", section on 'Laboratory testing'</a>.) </p><p></p><p class="bulletIndent1">A 2020 expert opinion practice guideline from the International Society on Haemostasis and Thrombosis (ISTH) recommends testing ristocetin-induced platelet activation (RIPA), followed by genetic testing [<a href="#rid85">85</a>]. In mixing studies, type 2B VWD plasma, but not platelet-type VWD plasma, increases the aggregation of control platelets by low concentrations of ristocetin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Standard management is discussed above; major bleeding can be treated with platelet transfusions [<a href="#rid85">85</a>]. For major bleeding that does not respond to platelet transfusions (or if transfusions are not available), rFVIIa can be used [<a href="#rid85">85</a>]. Minor bleeding can be treated with antifibrinolytic therapy and/or <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (DDAVP). </p><p></p><p class="bulletIndent1">If VWF activity is low, VWF concentrate is added. The target VWF activity is 50 to 60 percent for major bleeding or surgery and 30 to 50 percent for minor bleeding or surgery. (See  <a class="medical medical_review" href="/d/html/1372.html" rel="external">"von Willebrand disease (VWD): Treatment of major bleeding and major surgery", section on 'VWF concentrates for major bleeding'</a>.)</p><p></p><p class="headingAnchor" id="H16516971"><span class="h3">Quebec platelet disorder</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathophysiology </strong>– Quebec platelet disorder (QPD; originally called factor V Quebec) is caused by a pathogenic variant consisting of a duplication on chromosome 10 that includes <em>PLAU </em>and repositions a downstream megakaryocyte-specific enhancer that "rewires" <em>PLAU</em> to increase its expression selectively in megakaryocytes and platelets [<a href="#rid86">86-88</a>]. <em>PLAU </em>encodes the urokinase-type plasminogen activator (uPA), which cleaves plasminogen to plasmin. Generation of plasmin within platelets causes degradation of alpha granule contents including factor V, multimerin 1, VWF, and fibrinogen. QPD causes a gain-of-function defect in fibrinolysis as the release of uPA from QPD platelets accelerates fibrinolysis. (See  <a class="medical medical_review" href="/d/html/1326.html" rel="external">"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis", section on 'Quebec platelet disorder'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and inheritance</strong> – QPD affects approximately 1 in 200,000 French Canadians; all affected individuals share the same pathogenic variant [<a href="#rid21">21</a>]. Transmission is autosomal dominant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and evaluation</strong> – Patients with QPD have delayed-onset bleeding, including large hematomas and muscle and joint bleeding. Mild thrombocytopenia may be present, and platelet aggregometry shows reduced aggregation and absent secondary aggregation with epinephrine, with or without other aggregation abnormalities (reduced aggregation with ADP and collagen). (See <a class="local">'Platelet function testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The only effective treatment for QPD bleeding is antifibrinolytic therapy [<a href="#rid21">21</a>]. As several persons with QPD have developed thrombosis, concurrent anticoagulation and antifibrinolytic therapy should be considered during situations with high bleeding and high thrombotic risks including atrial fibrillation, pelvic fracture, and hip or knee replacement surgery [<a href="#rid62">62,63</a>]. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H3403392252"><span class="h3">Thrombocytopenia absent radius (TAR) syndrome</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathophysiology</strong> – Thrombocytopenia absent radius (TAR) syndrome is caused by pathogenic variants in the gene <em>RBM8A,</em> which encodes an mRNA binding protein involved in nuclear export of mRNA in many cell types. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and inheritance</strong> – TAR is extremely rare, with only a few hundred cases reported worldwide. Transmission is autosomal recessive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and evaluation</strong> – Radii are absent; thumbs are present. There may be other skeletal abnormalities, heart and genitourinary anomalies, and cow's milk intolerance. (See  <a class="medical medical_review" href="/d/html/16660.html" rel="external">"Microdeletion syndromes (chromosomes 1 to 11)", section on 'Proximal 1q21.1 deletion syndrome (Thrombocytopenia absent radius syndrome)'</a>.)</p><p></p><p class="bulletIndent1">Thrombocytopenia is initially severe (platelet counts &lt;50,000/microL) but gradually improves over time [<a href="#rid42">42</a>]. Bleeding risk may be greater than expected based on the platelet count.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Standard management is discussed above. Platelet transfusions are often required during early infancy and may also be required perioperatively, even in individuals whose platelet counts have improved [<a href="#rid42">42</a>]. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H2152857300"><span class="h3">Wiskott-Aldrich syndrome</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathophysiology</strong> – Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia (XLT) are caused by pathogenic variants in the <em>WAS </em>gene, which regulates actin cytoskeleton remodeling and cell polarization. WAS is a type of granule disorder (also called storage pool disorder). (See  <a class="medical medical_review" href="/d/html/3953.html" rel="external">"Wiskott-Aldrich syndrome", section on 'Pathogenesis'</a> and  <a class="medical medical_review" href="/d/html/3953.html" rel="external">"Wiskott-Aldrich syndrome", section on 'Genetics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and inheritance</strong> – The prevalence has been estimated at 1 to 10 per 1 million; it occurs almost exclusively in males. Transmission is X-linked. (See  <a class="medical medical_review" href="/d/html/3953.html" rel="external">"Wiskott-Aldrich syndrome", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and evaluation</strong> – Classical WAS is an immunodeficiency syndrome with T-cell dysfunction, autoimmunity, eczema, and an increased risk of hematologic malignancies. XLT is a less-severe form characterized mostly by thrombocytopenia and mild eczema.</p><p></p><p class="bulletIndent1">For both classical WAS and XLT, the complete blood count (CBC) and blood smear show a thrombocytopenia (platelet counts &lt;70,000/microL) and small platelets. (See <a class="local">'CBC, blood smear, coagulation testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment and prevention of bleeding</strong> – Standard management for bleeding is discussed above. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2">Patients with WAS are immunosuppressed. If platelet transfusions (or other blood product transfusions) are used, all products should be irradiated to avoid transfusion-associated graft-versus-host disease (TA-GVHD). Platelet transfusions should also be HLA-matched if possible, to avoid platelet alloimmunization [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/7928.html" rel="external">"Transfusion-associated graft-versus-host disease", section on 'Prevention'</a> and  <a class="medical medical_review" href="/d/html/7922.html" rel="external">"Refractoriness to platelet transfusion", section on 'Prevention'</a>.)</p><p></p><p class="bulletIndent2">Splenectomy may improve platelet counts but carries a risk of further immunosuppression and sepsis from encapsulated organisms [<a href="#rid19">19,42</a>]. Infection prevention and other considerations are discussed separately [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/117640.html" rel="external">"Elective (diagnostic or therapeutic) splenectomy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of immunodeficiency</strong> – Management of immunodeficiency in WAS is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3953.html" rel="external">"Wiskott-Aldrich syndrome", section on 'Treatment'</a>.)</p><p></p><p class="headingAnchor" id="H2674829521"><span class="h2">Normal platelet count</span></p><p class="headingAnchor" id="H510346890"><span class="h3">Chediak-Higashi syndrome</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathophysiology</strong> – Chediak-Higashi syndrome (CHS) is caused by pathogenic variants in the <em>LYST</em> gene, which encodes a protein involved in lysosomal trafficking in many cell types. Manifestations are due to impaired vesicle trafficking. (See  <a class="medical medical_review" href="/d/html/3926.html" rel="external">"Chediak-Higashi syndrome", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and inheritance</strong> – CHS is extremely rare with only a few hundred cases reported worldwide. Transmission is autosomal recessive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and evaluation</strong> – Clinical features include easy bruising and bleeding. White blood cells (WBCs) contain abnormally large cytoplasmic granules  (<a class="graphic graphic_picture graphicRef71313" href="/d/graphic/71313.html" rel="external">picture 2</a>).</p><p></p><p class="bulletIndent1">Patients with CHS have hypopigmentation (also called oculocutaneous albinism) and recurrent bacterial infections due to impaired immune function; some individuals may develop ataxia or neuropathies [<a href="#rid89">89</a>]. </p><p></p><p class="bulletIndent1">Disease progression to hemophagocytic lymphohistiocytosis (HLH) is common and often triggered by infection. This is referred to as the "accelerated phase" of CHS. HLH is a disorder of massive immune dysregulation with lymphohistiocytic infiltration of virtually all organ systems, fever, hepatosplenomegaly and lymphadenopathy, pancytopenia, and bleeding with hypofibrinogenemia. HLH is often fatal. (See  <a class="medical medical_review" href="/d/html/3926.html" rel="external">"Chediak-Higashi syndrome", section on 'Hemophagocytic lymphohistiocytosis/accelerated phase'</a> and  <a class="medical medical_review" href="/d/html/87499.html" rel="external">"Clinical features and diagnosis of hemophagocytic lymphohistiocytosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment and prevention of bleeding</strong> – Standard bleeding management and prevention are discussed above. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of immunodeficiency</strong> – Management of immune dysfunction mainly focuses on identification and treatment of infections. Hematopoietic stem cell transplant can be curative for the hematologic manifestations but not the neurologic complications. (See <a class="local">'Other treatments'</a> above and  <a class="medical medical_review" href="/d/html/3926.html" rel="external">"Chediak-Higashi syndrome", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/3926.html" rel="external">"Chediak-Higashi syndrome", section on 'Prognosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of HLH</strong> – (See  <a class="medical medical_review" href="/d/html/8384.html" rel="external">"Treatment and prognosis of hemophagocytic lymphohistiocytosis"</a>.)</p><p></p><p class="headingAnchor" id="H4079308052"><span class="h3">Glanzmann thrombasthenia</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathophysiology</strong> – Glanzmann thrombasthenia (GT) is caused by pathogenic variants in <em>ITGA2B </em>and<em> ITGB3</em>.<em> </em>These genes<em> </em>encode components of the integrin alphaIIbbeta3 (previously called GPIIb/IIIa), which serves as one of the platelet receptors for VWF [<a href="#rid90">90</a>]. GT platelets have reduced adherence to VWF at sites of vascular injury (but they can still adhere via GPIb/IX). (See  <a class="medical medical_review" href="/d/html/1309.html" rel="external">"Pathophysiology of von Willebrand disease", section on 'VWF functions'</a>.)</p><p></p><p class="bulletIndent1">Leukocyte adhesion deficiency III (LAD-III) is another rare disorder of integrin function, due to pathogenic variants in the gene <em>FERMT3</em> (also called <em>KINDLIN3</em>), which has a role in integrin activation in hematopoietic cells. LAD-III is associated with reduced alphaIIbbeta3 expression and a GT phenotype [<a href="#rid91">91</a>]. (See  <a class="medical medical_review" href="/d/html/3918.html" rel="external">"Leukocyte-adhesion deficiency", section on 'LAD III'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and inheritance</strong> – The prevalence is approximately 1 in 1 million. Transmission is autosomal recessive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and evaluation</strong> – GT generally presents with a bleeding phenotype with a normal platelet count and normal platelet size. There are no other syndromic features. The diagnosis can be made by platelet aggregometry. GT platelets do not aggregate in response to ADP (first or second wave) or collagen; only ristocetin-induced aggregation is normal  (<a class="graphic graphic_table graphicRef69518" href="/d/graphic/69518.html" rel="external">table 2</a>). This is the converse pattern of BSS. (See <a class="local">'Bernard-Soulier syndrome'</a> above.)</p><p></p><p class="bulletIndent1">Individuals with GT who have received multiple platelet transfusions can sometimes develop alloantibodies to integrin alphaIIbbeta3 and/or HLA antigens, resulting in refractoriness to such transfusion. Rare cases of acquired GT due to allo- or autoantibodies have been reported [<a href="#rid92">92-99</a>]. (See  <a class="medical medical_review" href="/d/html/7922.html" rel="external">"Refractoriness to platelet transfusion", section on 'Alloimmunization'</a>.)</p><p></p><p class="bulletIndent1">Infants with LAD-III can have leukocytosis, delayed separation of the umbilical cord, and severe bacterial infections. (See  <a class="medical medical_review" href="/d/html/3918.html" rel="external">"Leukocyte-adhesion deficiency", section on 'LAD III'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Standard management decisions are discussed above. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1">Unique to GT is the risk of developing alloantibodies to integrin alphaIIbbeta3 and/or HLA antigens, resulting in refractoriness to platelet transfusions. This leads to the risk that a more serious bleeding event in the future could not be effectively treated with platelet transfusions. As a result, many clinicians will use recombinant activated factor VII (rFVIIa) for minor or less-serious bleeding in an attempt to "save" platelet transfusions for truly life-threatening bleeding. Dosing is discussed above, and the general approach is discussed in more detail separately. HLA-matched platelets are indicated, where available. (See <a class="local">'Recombinant factor VIIa'</a> above and  <a class="medical medical_review" href="/d/html/1341.html" rel="external">"Recombinant factor VIIa: Administration and adverse effects", section on 'Glanzmann thrombasthenia'</a>.)</p><p></p><p class="bulletIndent1">Hematopoietic stem cell transplantation has been successfully used in some patients who have severe bleeding and/or development of antiplatelet antibodies [<a href="#rid100">100-104</a>]. (See <a class="local">'Other treatments'</a> above.)</p><p></p><p class="headingAnchor" id="H272836633"><span class="h3">Hermansky-Pudlak syndrome</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathophysiology</strong> – Hermansky-Pudlak syndrome (HPS) is caused by biallelic pathogenic variants in one of the genes listed in the table  (<a class="graphic graphic_table graphicRef115599" href="/d/graphic/115599.html" rel="external">table 4</a>). These encode components of complexes involved in intracellular biogenesis and trafficking of lysosomes and lysosome-related organelles (LROS). (See  <a class="medical medical_review" href="/d/html/115158.html" rel="external">"Hermansky-Pudlak syndrome", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and inheritance</strong> – The prevalence is approximately 1 in 1 million or slightly greater; there is a high carrier frequency in Puerto Rico. Transmission is autosomal recessive. (See  <a class="medical medical_review" href="/d/html/115158.html" rel="external">"Hermansky-Pudlak syndrome", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and evaluation</strong> – Hypopigmentation and platelet dysfunction are present in all individuals. Other manifestations are variable depending on the affected gene, including pulmonary fibrosis colitis, neutropenia, and immunodeficiency. (See  <a class="medical medical_review" href="/d/html/115158.html" rel="external">"Hermansky-Pudlak syndrome", section on 'Clinical manifestations'</a>.) </p><p></p><p class="bulletIndent1">The platelet count is normal. The blood smear shows pale platelets.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment and prevention of bleeding</strong> – Standard bleed management is discussed above. (See <a class="local">'Treatment'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of other manifestations</strong> (dermatologic, ophthalmic, gastrointestinal, respiratory) – (See  <a class="medical medical_review" href="/d/html/115158.html" rel="external">"Hermansky-Pudlak syndrome", section on 'Management'</a>.)</p><p></p><p class="headingAnchor" id="H3000066012"><span class="h3">Scott syndrome</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathophysiology</strong> – Scott syndrome is caused by pathogenic variants in <em>ANO6 </em>(previously called<em> TMEM16F</em>). <em>ANO6</em> encodes a calcium-activated transmembrane enzyme with "flippase" activity, which redistributes negatively charged phosphatidyl serine (PS) and phosphatidyl ethanolamine (PE) from the platelet membrane leaflet to the outer leaflet [<a href="#rid105">105</a>]. As a result, these membrane phospholipids cannot get redistributed to the outer membrane in response to platelet agonists and cannot form a phospholipid scaffold for assembly of the tenase and prothrombinase complexes [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Multicomponent complexes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and inheritance</strong> – The syndrome is extremely rare. Transmission is autosomal dominant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and evaluation</strong> – Platelet count and platelet size are normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Standard management is discussed above. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H2283144595"><span class="h2">Hereditary thrombocytopenia with normal platelet function</span><span class="headingEndMark"> — </span>Hereditary disorders of decreased platelet production or increased platelet clearance cause thrombocytopenia without affecting platelet function.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital amegakaryocytic thrombocytopenia (CAMT)</strong> – Variants in the <em>MPL</em> gene, which encodes the thrombopoietin receptor, cause CAMT. (See  <a class="medical medical_review" href="/d/html/5921.html" rel="external">"Causes of thrombocytopenia in children", section on 'Inherited platelet disorders'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Montreal platelet syndrome (type 2B VWD)</strong> – Montreal platelet syndrome is a form of type 2B VWD caused by a V1316M mutation in the <em>VWF</em> gene [<a href="#rid106">106</a>]. (See  <a class="medical medical_review" href="/d/html/1309.html" rel="external">"Pathophysiology of von Willebrand disease", section on 'Type 2 (dysfunctional protein; 2A, 2B, 2M, 2N)'</a> and  <a class="medical medical_review" href="/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease", section on 'Summary of VWD types'</a>.)</p><p></p><p class="headingAnchor" id="H2541541385"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/105473.html" rel="external">"Society guideline links: Immune thrombocytopenia (ITP) and other platelet disorders"</a>.)</p><p class="headingAnchor" id="H28268253"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Platelets bind collagen and von Willebrand factor (VWF) at sites of vascular injury, which triggers activation, secretion of granule contents, aggregation, binding to clotting factors, and thrombin generation. Inherited platelet function disorders (IPFDs) can affect any of these processes. Some disorders cause thrombocytopenia and/or alter platelet size; some are associated with syndromic features. (See <a class="local">'Conceptual framework'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>When to suspect</strong> – IPFDs can present with excess bleeding (especially heavy menstrual bleeding), thrombocytopenia, abnormal platelet morphology, syndromic features, or after diagnosis in a relative. Diagnosis is frequently delayed. All evaluations should start with a bleeding assessment tool (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbleedingscore.certe.nl%2F&amp;token=Nn2kz6P9LalXZBakWq4EFVy%2FtKzfMxWmVZgnncoM9zqnY8WwoOfYCEf5tSBri%2Fvl&amp;TOPIC_ID=6675" target="_blank">ISTH-BAT</a>). Syndromic features (hypopigmentation, eczema) should be assessed. (See <a class="local">'When to suspect'</a> above and <a class="local">'History and examination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory</strong> – Obtain a complete blood count (CBC), metabolic panel, liver function tests, clotting studies, fibrinogen, and VWD testing. If this is unrevealing  (<a class="graphic graphic_algorithm graphicRef138359" href="/d/graphic/138359.html" rel="external">algorithm 1</a>), platelet aggregometry is indicated  (<a class="graphic graphic_table graphicRef69518" href="/d/graphic/69518.html" rel="external">table 2</a>). Genetic testing can be confirmatory and can facilitate testing of first-degree relatives if symptomatic. Aggregometry and genetic testing should be ordered by a hematologist or other hemostasis expert. (See <a class="local">'Platelet function testing'</a> above and <a class="local">'Genetic testing'</a> above and  <a class="medical medical_review" href="/d/html/4433.html" rel="external">"Platelet function testing", section on 'Platelet aggregometry'</a>.) </p><p></p><p class="bulletIndent2">Iron deficiency may occur when bleeding has been significant. Serum ferritin is used to assess for iron deficiency. (See <a class="local">'Iron deficiency'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Differential</strong> – The differential diagnosis includes other bleeding disorders, thrombocytopenias, and drug effects. (See  <a class="medical medical_review" href="/d/html/5936.html" rel="external">"Approach to the child with bleeding symptoms"</a> and  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a> and  <a class="medical medical_review" href="/d/html/5939.html" rel="external">"Approach to the child with unexplained thrombocytopenia"</a> and  <a class="medical medical_review" href="/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Management should involve consultation with a hemophilia treatment center, ideally at the time of diagnosis to allow planning. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bleeding/surgery</strong> – Platelet transfusion is the main therapy for major bleeding or surgery. Recombinant activated factor VII (rFVIIa) may be used in selected cases. For individuals with Glanzmann thrombasthenia (GT) who have non-major bleeding, we suggest rFVIIa rather than platelet transfusions (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This preserves platelet transfusions for life-threatening bleeding or major surgery, since platelet transfusion can result in alloantibody formation that can render future transfusions less effective. This may apply to other IPFDs. (See <a class="local">'Major bleeding or major surgery'</a> above.)</p><p></p><p class="bulletIndent2">Minor bleeding can be treated with local therapies (nasal packing, cautery), antifibrinolytic agents, and <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (DDAVP). (See <a class="local">'Major bleeding or major surgery'</a> above and <a class="local">'Minor bleeding or minor procedures'</a> above.)</p><p></p><p class="bulletIndent2">Thrombopoietin receptor agonists (TPO-RAs) are occasionally used for chronic therapy or elective surgery, but evidence is limited. Hematopoietic stem cell transplantation is reserved for severe frequent bleeding. Syndromic features may require separate interventions. (See <a class="local">'Iron deficiency'</a> above and <a class="local">'Other treatments'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnancy </strong>– Bleeding risk is greatest during delivery and postpartum; platelet transfusions may be required. All individuals should receive antifibrinolytic therapy. Neuraxial anesthesia will be associated with increased complication rates; consultation with anesthesia is recommended before delivery. Those with alloantibodies may have fetal and neonatal alloimmune thrombocytopenia (NAIT). (See <a class="local">'Obstetric considerations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Counseling </strong>– Individuals with IPFDs should be aware of drugs and medications to avoid and should inform clinicians about their disorder. Carrying a wallet card and/or registration with national databases can be helpful. First-degree relatives should have the opportunity to be evaluated. (See <a class="local">'Counseling and communication'</a> above and <a class="local">'Implications for first-degree relatives'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific platelet function disorders</strong> – (See <a class="local">'Specific disorders'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombocytopenia</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>BSS – (See <a class="local">'Bernard-Soulier syndrome'</a> above.)</p><p class="bulletIndent3"><span class="glyph">-</span>Gray platelet – (See <a class="local">'Gray platelet syndrome'</a> above.)</p><p class="bulletIndent3"><span class="glyph">-</span>GPVI – (See <a class="local">'GPVI deficiency'</a> above.)</p><p class="bulletIndent3"><span class="glyph">-</span>MYH9 – (See <a class="local">'MYH9-related disease'</a> above.)</p><p class="bulletIndent3"><span class="glyph">-</span>Paris-Trousseau – (See <a class="local">'Paris-Trousseau syndrome'</a> above.)</p><p class="bulletIndent3"><span class="glyph">-</span>Platelet-type VWD – (See <a class="local">'Platelet-type VWD'</a> above.)</p><p class="bulletIndent3"><span class="glyph">-</span>Quebec – (See <a class="local">'Quebec platelet disorder'</a> above.)</p><p class="bulletIndent3"><span class="glyph">-</span>TAR – (See <a class="local">'Thrombocytopenia absent radius (TAR) syndrome'</a> above.)</p><p class="bulletIndent3"><span class="glyph">-</span>Wiskott-Aldrich – (See <a class="local">'Wiskott-Aldrich syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normal platelet count </strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Chediak-Higashi – (See <a class="local">'Chediak-Higashi syndrome'</a> above.)</p><p class="bulletIndent3"><span class="glyph">-</span>GT – (See <a class="local">'Glanzmann thrombasthenia'</a> above.)</p><p class="bulletIndent3"><span class="glyph">-</span>Hermansky-Pudlak – (See <a class="local">'Hermansky-Pudlak syndrome'</a> above.)</p><p class="bulletIndent3"><span class="glyph">-</span>Scott – (See <a class="local">'Scott syndrome'</a> above.)</p><p></p><p class="headingAnchor" id="H1935006938"><span class="h1">ACKNOWLEDGMENTS</span></p><p>The UpToDate editorial staff acknowledges Steven Coutre, MD (deceased), who contributed to earlier versions of this topic review.</p><p>The UpToDate editorial staff also acknowledges Lawrence LK Leung, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bourguignon A, Tasneem S, Hayward CPM. Update on platelet procoagulant mechanisms in health and in bleeding disorders. Int J Lab Hematol 2022; 44 Suppl 1:89.</a></li><li><a class="nounderline abstract_t">Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003; 102:449.</a></li><li><a class="nounderline abstract_t">Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res 2007; 100:1673.</a></li><li><a class="nounderline abstract_t">Nachman RL, Rafii S. Platelets, petechiae, and preservation of the vascular wall. N Engl J Med 2008; 359:1261.</a></li><li><a class="nounderline abstract_t">Bryckaert M, Rosa JP, Denis CV, Lenting PJ. Of von Willebrand factor and platelets. Cell Mol Life Sci 2015; 72:307.</a></li><li><a class="nounderline abstract_t">Roberts W, Magwenzi S, Aburima A, Naseem KM. Thrombospondin-1 induces platelet activation through CD36-dependent inhibition of the cAMP/protein kinase A signaling cascade. Blood 2010; 116:4297.</a></li><li><a class="nounderline abstract_t">Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 2008; 28:403.</a></li><li><a class="nounderline abstract_t">Janus-Bell E, Yakusheva A, Scandola C, et al. Characterization of the Role of Integrin α5β1 in Platelet Function, Hemostasis, and Experimental Thrombosis. Thromb Haemost 2022; 122:767.</a></li><li><a class="nounderline abstract_t">Lickert S, Kenny M, Selcuk K, et al. Platelets drive fibronectin fibrillogenesis using integrin αIIbβ3. Sci Adv 2022; 8:eabj8331.</a></li><li><a class="nounderline abstract_t">Sharma P, Nicoli ER, Serra-Vinardell J, et al. Chediak-Higashi syndrome: a review of the past, present, and future. Drug Discov Today Dis Models 2020; 31:31.</a></li><li><a class="nounderline abstract_t">Cattaneo M. The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 2011; 117:2102.</a></li><li><a class="nounderline abstract_t">Morison IM, Cramer Bordé EM, Cheesman EJ, et al. A mutation of human cytochrome c enhances the intrinsic apoptotic pathway but causes only thrombocytopenia. Nat Genet 2008; 40:387.</a></li><li><a class="nounderline abstract_t">Levin C, Koren A, Pretorius E, et al. Deleterious mutation in the FYB gene is associated with congenital autosomal recessive small-platelet thrombocytopenia. J Thromb Haemost 2015; 13:1285.</a></li><li><a class="nounderline abstract_t">Levin C, Zalman L, Tamary H, et al. Small-platelet thrombocytopenia in a family with autosomal recessive inheritance pattern. Pediatr Blood Cancer 2013; 60:E128.</a></li><li><a class="nounderline abstract_t">Berrou E, Soukaseum C, Favier R, et al. A mutation of the human EPHB2 gene leads to a major platelet functional defect. Blood 2018; 132:2067.</a></li><li><a class="nounderline abstract_t">Brunet J, Badin M, Chong M, et al. Bleeding risks for uncharacterized platelet function disorders. Res Pract Thromb Haemost 2020; 4:799.</a></li><li><a class="nounderline abstract_t">Gresele P, Orsini S, Noris P, et al. Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. J Thromb Haemost 2020; 18:732.</a></li><li><a class="nounderline abstract_t">Bourguignon A, Tasneem S, Hayward CP. Screening and diagnosis of inherited platelet disorders. Crit Rev Clin Lab Sci 2022; 59:405.</a></li><li><a class="nounderline abstract_t">Balduini CL. Treatment of inherited thrombocytopenias. Haematologica 2022; 107:1278.</a></li><li><a class="nounderline abstract_t">Gresele P, Subcommittee on Platelet Physiology of the International Society on Thrombosis and Hemostasis. Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. J Thromb Haemost 2015; 13:314.</a></li><li><a class="nounderline abstract_t">McKay H, Derome F, Haq MA, et al. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood 2004; 104:159.</a></li><li><a class="nounderline abstract_t">Gresele P, Falcinelli E, Bury L, et al. The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost 2021; 19:1364.</a></li><li><a class="nounderline abstract_t">Drouin A, Favier R, Massé JM, et al. Newly recognized cellular abnormalities in the gray platelet syndrome. Blood 2001; 98:1382.</a></li><li><a class="nounderline abstract_t">Gunay-Aygun M, Zivony-Elboum Y, Gumruk F, et al. Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p. Blood 2010; 116:4990.</a></li><li><a class="nounderline abstract_t">Ferreira CR, Chen D, Abraham SM, et al. Combined alpha-delta platelet storage pool deficiency is associated with mutations in GFI1B. Mol Genet Metab 2017; 120:288.</a></li><li><a class="nounderline abstract_t">Castilloux JF, Moffat KA, Liu Y, et al. A prospective cohort study of light transmission platelet aggregometry for bleeding disorders: is testing native platelet-rich plasma non-inferior to testing platelet count adjusted samples? Thromb Haemost 2011; 106:675.</a></li><li><a class="nounderline abstract_t">Hayward CP, Pai M, Liu Y, et al. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost 2009; 7:676.</a></li><li><a class="nounderline abstract_t">Brunet JG, Iyer JK, Badin MS, et al. Electron microscopy examination of platelet whole mount preparations to quantitate platelet dense granule numbers: Implications for diagnosing suspected platelet function disorders due to dense granule deficiency. Int J Lab Hematol 2018; 40:400.</a></li><li><a class="nounderline abstract_t">Mezzano D, Harrison P, Frelinger AL 3rd, et al. Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost 2022; 20:2127.</a></li><li><a class="nounderline abstract_t">Badin MS, Graf L, Iyer JK, et al. Variability in platelet dense granule adenosine triphosphate release findings amongst patients tested multiple times as part of an assessment for a bleeding disorder. Int J Lab Hematol 2016; 38:648.</a></li><li><a class="nounderline abstract_t">Frelinger AL 3rd, Rivera J, Connor DE, et al. Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost 2021; 19:3193.</a></li><li><a class="nounderline abstract_t">Lassila R. Platelet Function Tests in Bleeding Disorders. Semin Thromb Hemost 2016; 42:185.</a></li><li><a class="nounderline abstract_t">Hayward CP, Harrison P, Cattaneo M, et al. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4:312.</a></li><li><a class="nounderline abstract_t">Watson SP, Lowe GC, Lordkipanidzé M, et al. Genotyping and phenotyping of platelet function disorders. J Thromb Haemost 2013; 11 Suppl 1:351.</a></li><li><a class="nounderline abstract_t">Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64:1.</a></li><li><a class="nounderline abstract_t">Landolfi R, Marchioli R, Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost 1997; 78:617.</a></li><li><a class="nounderline abstract_t">Pareti FI, Gugliotta L, Mannucci L, et al. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders. Thromb Haemost 1982; 47:84.</a></li><li><a class="nounderline abstract_t">Kaywin P, McDonough M, Insel PA, Shattil SJ. Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors. N Engl J Med 1978; 299:505.</a></li><li><a class="nounderline abstract_t">Lopez-Vilchez I, Jerez-Dolz D, Diaz-Ricart M, et al. Escitalopram Impairs Thrombin-Induced Platelet Response, Cytoskeletal Assembly and Activation of Associated Signalling Pathways. Thromb Haemost 2017; 117:2312.</a></li><li><a class="nounderline abstract_t">Hirsh-Rokach B, Spectre G, Shai E, et al. Differential impact of selective serotonin reuptake inhibitors on platelet response to clopidogrel: a randomized, double-blind, crossover trial. Pharmacotherapy 2015; 35:140.</a></li><li><a class="nounderline abstract_t">Serebruany VL, Glassman AH, Malinin AI, et al. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail 2003; 5:517.</a></li><li><a class="nounderline abstract_t">Bolton-Maggs PH, Chalmers EA, Collins PW, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006; 135:603.</a></li><li><a class="nounderline abstract_t">Bastida JM, Gonzalez-Porras JR, Rivera J, Lozano ML. Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia. Int J Mol Sci 2021; 22.</a></li><li><a class="nounderline abstract_t">Alamelu J, Liesner R. Modern management of severe platelet function disorders. Br J Haematol 2010; 149:813.</a></li><li><a class="nounderline abstract_t">Poon MC. The Use of Recombinant Activated Factor VII in Patients with Glanzmann's Thrombasthenia. Thromb Haemost 2021; 121:332.</a></li><li><a class="nounderline abstract_t">Lee RH, Kasthuri RS, Bergmeier W. Platelet transfusion for patients with platelet dysfunction: effectiveness, mechanisms, and unanswered questions. Curr Opin Hematol 2020; 27:378.</a></li><li><a class="nounderline abstract_t">Kopolovic I, Ostro J, Tsubota H, et al. A systematic review of transfusion-associated graft-versus-host disease. Blood 2015; 126:406.</a></li><li><a class="nounderline abstract_t">Galán AM, Tonda R, Pino M, et al. Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders. Transfusion 2003; 43:885.</a></li><li><a class="nounderline abstract_t">Lisman T, Moschatsis S, Adelmeijer J, et al. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 2003; 101:1864.</a></li><li><a class="nounderline abstract_t">Wilbourn B, Harrison P, Mackie IJ, et al. Activation of platelets in whole blood by recombinant factor VIIa by a thrombin-dependent mechanism. Br J Haematol 2003; 122:651.</a></li><li><a class="nounderline abstract_t">Lisman T, Adelmeijer J, Heijnen HF, de Groot PG. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. Blood 2004; 103:1720.</a></li><li><a class="nounderline abstract_t">Gabriel DA, Li X, Monroe DM 3rd, Roberts HR. Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets. J Thromb Haemost 2004; 2:1816.</a></li><li><a class="nounderline abstract_t">Lee A, Maier CL, Batsuli G. Iron deficiency anemia and bleeding management in pediatric patients with Bernard-Soulier syndrome and Glanzmann Thrombasthenia: A single-institution analysis. Haemophilia 2022; 28:633.</a></li><li><a class="nounderline abstract_t">Laguna P. Use of rFVIIa in Preventing Recurrent Intra-articular Hemorrhages in a 15-Year-Old Patient With Glanzmann Thrombasthenia. J Pediatr Hematol Oncol 2021; 43:e1120.</a></li><li><a class="nounderline abstract_t">Andiç N, Oğuz N, Gündüz E, et al. Weekly low-dose recombinant factor VIIa prophylaxis in Glanzmann thrombasthenia. Blood Coagul Fibrinolysis 2021; 32:349.</a></li><li><a class="nounderline abstract_t">DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 1990; 33:39.</a></li><li><a class="nounderline abstract_t">Cattaneo M. Desmopressin in the treatment of patients with defects of platelet function. Haematologica 2002; 87:1122.</a></li><li><a class="nounderline abstract_t">Colucci G, Stutz M, Rochat S, et al. The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects. Blood 2014; 123:1905.</a></li><li><a class="nounderline abstract_t">Kosch A, Kehrel B, Nowak-Göttl U, et al. [Thrombocytic alpha-delta-storage-pool-disease: shortening of bleeding time after infusion of 1-desamino-8-D-arginine vasopressin]. Klin Padiatr 1999; 211:198.</a></li><li><a class="nounderline abstract_t">Piot B, Sigaud-Fiks M, Huet P, et al. Management of dental extractions in patients with bleeding disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93:247.</a></li><li><a class="nounderline abstract_t">Taeuber I, Weibel S, Herrmann E, et al. Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality: A Systematic Review, Meta-analysis, and Meta-regression. JAMA Surg 2021; :e210884.</a></li><li><a class="nounderline abstract_t">Goodliffe L, Ainsworth C, Whitlock RP, et al. Management of a Left Atrial Appendage Thrombus Due to Atrial Fibrillation Complicating Québec Platelet Disorder. Can J Cardiol 2022; 38:1464.</a></li><li><a class="nounderline abstract_t">Hayward CPM, Tasneem S, Rivard GE. Improved platelet counts during prolonged tranexamic therapy for Quebec platelet disorder implicate the underlying fibrinolytic defect as the cause of lower platelet counts. Int J Lab Hematol 2020; 42:e274.</a></li><li><a class="nounderline abstract_t">Zaninetti C, Gresele P, Bertomoro A, et al. Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial. Haematologica 2020; 105:820.</a></li><li><a class="nounderline abstract_t">Khoreva A, Abramova I, Deripapa E, et al. Efficacy of romiplostim in treatment of thrombocytopenia in children with Wiskott-Aldrich syndrome. Br J Haematol 2021; 192:366.</a></li><li><a class="nounderline abstract_t">Gerrits AJ, Leven EA, Frelinger AL 3rd, et al. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood 2015; 126:1367.</a></li><li><a class="nounderline abstract_t">Rabbolini DJ, Chun Y, Latimer M, et al. Diagnosis and treatment of MYH9-RD in an Australasian cohort with thrombocytopenia. Platelets 2018; 29:793.</a></li><li><a class="nounderline abstract_t">Pecci A, Gresele P, Klersy C, et al. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood 2010; 116:5832.</a></li><li><a class="nounderline abstract_t">Cancio M, Hebert K, Kim S, et al. Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia. Transplant Cell Ther 2022; 28:101.e1.</a></li><li><a class="nounderline abstract_t">Albert MH, Slatter MA, Gennery AR, et al. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis. Blood 2022; 139:2066.</a></li><li><a class="nounderline abstract_t">Fiore M, Sentilhes L, d'Oiron R. How I manage pregnancy in women with Glanzmann thrombasthenia. Blood 2022; 139:2632.</a></li><li><a class="nounderline abstract_t">Punt MC, Ruigrok ND, Bloemenkamp KWM, et al. Obstetrical bleeding in women with MYH9-related disease-A systematic review. Haemophilia 2021; 27:e278.</a></li><li><a class="nounderline abstract_t">Nurden P, Nurden AT. Congenital disorders associated with platelet dysfunctions. Thromb Haemost 2008; 99:253.</a></li><li><a class="nounderline abstract_t">Wei AH, Schoenwaelder SM, Andrews RK, Jackson SP. New insights into the haemostatic function of platelets. Br J Haematol 2009; 147:415.</a></li><li><a class="nounderline abstract_t">Noris P, Perrotta S, Seri M, et al. Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood 2011; 117:6673.</a></li><li><a class="nounderline abstract_t">Savoia A, Pastore A, De Rocco D, et al. Clinical and genetic aspects of Bernard-Soulier syndrome: searching for genotype/phenotype correlations. Haematologica 2011; 96:417.</a></li><li><a class="nounderline abstract_t">Sumitha E, Jayandharan GR, David S, et al. Molecular basis of Bernard-Soulier syndrome in 27 patients from India. J Thromb Haemost 2011; 9:1590.</a></li><li><a class="nounderline abstract_t">Boeckelmann D, Hengartner H, Greinacher A, et al. Patients with Bernard-Soulier syndrome and different severity of the bleeding phenotype. Blood Cells Mol Dis 2017; 67:69.</a></li><li><a class="nounderline abstract_t">Gunay-Aygun M, Falik-Zaccai TC, Vilboux T, et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules. Nat Genet 2011; 43:732.</a></li><li><a class="nounderline abstract_t">Arthur JF, Dunkley S, Andrews RK. Platelet glycoprotein VI-related clinical defects. Br J Haematol 2007; 139:363.</a></li><li><a class="nounderline abstract_t">Asensio-Juárez G, Llorente-González C, Vicente-Manzanares M. Linking the Landscape of MYH9-Related Diseases to the Molecular Mechanisms that Control Non-Muscle Myosin II-A Function in Cells. Cells 2020; 9.</a></li><li><a class="nounderline abstract_t">Fernandez-Prado R, Carriazo-Julio SM, Torra R, et al. MYH9-related disease: it does exist, may be more frequent than you think and requires specific therapy. Clin Kidney J 2019; 12:488.</a></li><li><a class="nounderline abstract_t">Savoia A, De Rocco D, Panza E, et al. Heavy chain myosin 9-related disease (MYH9 -RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. Thromb Haemost 2010; 103:826.</a></li><li><a class="nounderline abstract_t">Peddu D, Amin S, Ying YM. Characterization of Sensorineural Hearing Loss in Patients With MYH9-Related Disease: A Systematic Review. Otol Neurotol 2022; 43:e298.</a></li><li><a class="nounderline abstract_t">Othman M, Gresele P. Guidance on the diagnosis and management of platelet-type von Willebrand disease: A communication from the Platelet Physiology Subcommittee of the ISTH. J Thromb Haemost 2020; 18:1855.</a></li><li><a class="nounderline abstract_t">Diamandis M, Paterson AD, Rommens JM, et al. Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes. Blood 2009; 113:1543.</a></li><li><a class="nounderline abstract_t">Liang M, Soomro A, Tasneem S, et al. Enhancer-gene rewiring in the pathogenesis of Quebec platelet disorder. Blood 2020; 136:2679.</a></li><li><a class="nounderline abstract_t">Tracy PB, Giles AR, Mann KG, et al. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency. J Clin Invest 1984; 74:1221.</a></li><li class="breakAll">Ajitkumar A, Yarrarapu SNS, Ramphul K.. StatPearls, StatPearls Publishing, Treasure Island (FL) 2022.</li><li><a class="nounderline abstract_t">Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 2011; 118:5996.</a></li><li><a class="nounderline abstract_t">Svensson L, Howarth K, McDowall A, et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat Med 2009; 15:306.</a></li><li><a class="nounderline abstract_t">Granel B, Swiader L, Veit V, et al. [Pseudo-Glanzmann thrombasthenia in the course of autoimmune thrombocytopenic purpura]. Rev Med Interne 1998; 19:823.</a></li><li><a class="nounderline abstract_t">Meyer M, Kirchmaier CM, Schirmer A, et al. Acquired disorder of platelet function associated with autoantibodies against membrane glycoprotein IIb-IIIa complex--1. Glycoprotein analysis. Thromb Haemost 1991; 65:491.</a></li><li><a class="nounderline abstract_t">Tholouli E, Hay CR, O'Gorman P, Makris M. Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder. Br J Haematol 2004; 127:209.</a></li><li><a class="nounderline abstract_t">McMillan R. The role of antiplatelet autoantibody assays in the diagnosis of immune thrombocytopenic purpura. Curr Hematol Rep 2005; 4:160.</a></li><li><a class="nounderline abstract_t">Yee NS, Schuster SJ. Clinical remission of acquired thrombasthenia with low-dose methotrexate in a patient with systemic lupus erythematosus. Mayo Clin Proc 2006; 81:566.</a></li><li><a class="nounderline abstract_t">Peaceman AM, Katz AR, Laville M. Bernard-Soulier syndrome complicating pregnancy: a case report. Obstet Gynecol 1989; 73:457.</a></li><li><a class="nounderline abstract_t">Bierling P, Fromont P, Elbez A, et al. Early immunization against platelet glycoprotein IIIa in a newborn Glanzmann type I patient. Vox Sang 1988; 55:109.</a></li><li><a class="nounderline abstract_t">Constantinescu-Bercu A, McCann S, Hmaid A, et al. Acquired Glanzmann's thrombasthenia with IgG and IgA against activated αIIb β3. Br J Haematol 2023; 202:e58.</a></li><li><a class="nounderline abstract_t">Connor P, Khair K, Liesner R, et al. Stem cell transplantation for children with Glanzmann thrombasthenia. Br J Haematol 2008; 140:568.</a></li><li><a class="nounderline abstract_t">Li JH, Sun SW, Ai Y, et al. Excellent Outcome Following Sibling Peripheral Blood Hematopoietic Stem Cell Transplantation for Glanzmann Thrombasthenia: A Case Report. Front Pediatr 2021; 9:776927.</a></li><li><a class="nounderline abstract_t">Friend BD, Roach GD, Kempert PH, Moore TB. Successful Use of Hematopoietic Stem Cell Transplantation for 2 Pediatric Cases of Glanzmann Thrombasthenia and Review of the Literature. J Pediatr Hematol Oncol 2020; 42:e521.</a></li><li><a class="nounderline abstract_t">Cid AR, Montesinos P, Sánchez-Guiu I, et al. Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia. Clin Case Rep 2017; 5:1887.</a></li><li><a class="nounderline abstract_t">Wiegering V, Sauer K, Winkler B, et al. Indication for allogeneic stem cell transplantation in Glanzmann's thrombasthenia. Hamostaseologie 2013; 33:305.</a></li><li><a class="nounderline abstract_t">Nurden P, Stritt S, Favier R, Nurden AT. Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy. Haematologica 2021; 106:337.</a></li><li><a class="nounderline abstract_t">Jackson SC, Sinclair GD, Cloutier S, et al. The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood 2009; 113:3348.</a></li></ol></div><div id="topicVersionRevision">Topic 6675 Version 52.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36074709" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Update on platelet procoagulant mechanisms in health and in bleeding disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12649139" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Platelet-collagen interaction: is GPVI the central receptor?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17585075" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Adhesion mechanisms in platelet function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18799560" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Platelets, petechiae, and preservation of the vascular wall.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25297919" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Of von Willebrand factor and platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664056" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Thrombospondin-1 induces platelet activation through CD36-dependent inhibition of the cAMP/protein kinase A signaling cascade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18174460" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cell adhesion mechanisms in platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34598304" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Characterization of the Role of Integrinα5β1 in Platelet Function, Hemostasis, and Experimental Thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35275711" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Platelets drive fibronectin fibrillogenesis using integrinαIIbβ3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33424983" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Chediak-Higashi syndrome: a review of the past, present, and future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20966167" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The platelet P2Y₁₂receptor for adenosine diphosphate: congenital and drug-induced defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18345000" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A mutation of human cytochrome c enhances the intrinsic apoptotic pathway but causes only thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25876182" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Deleterious mutation in the FYB gene is associated with congenital autosomal recessive small-platelet thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23650215" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Small-platelet thrombocytopenia in a family with autosomal recessive inheritance pattern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30213874" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A mutation of the human EPHB2 gene leads to a major platelet functional defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32685888" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bleeding risks for uncharacterized platelet function disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31750621" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35341454" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Screening and diagnosis of inherited platelet disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35642487" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment of inherited thrombocytopenias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25403439" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15026313" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Bleeding risks associated with inheritance of the Quebec platelet disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33880867" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11520786" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Newly recognized cellular abnormalities in the gray platelet syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20709904" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28041820" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Combined alpha-delta platelet storage pool deficiency is associated with mutations in GFI1B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21947061" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A prospective cohort study of light transmission platelet aggregometry for bleeding disorders: is testing native platelet-rich plasma non-inferior to testing platelet count adjusted samples?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19143930" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29508516" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Electron microscopy examination of platelet whole mount preparations to quantitate platelet dense granule numbers: Implications for diagnosing suspected platelet function disorders due to dense granule deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35770723" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27571881" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Variability in platelet dense granule adenosine triphosphate release findings amongst patients tested multiple times as part of an assessment for a bleeding disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34580997" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26886396" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Platelet Function Tests in Bleeding Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16420557" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23516995" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Genotyping and phenotyping of platelet function disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6375757" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Bleeding and thrombosis in the myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9198226" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mechanisms of bleeding and thrombosis in myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7101243" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/210377" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29212119" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Escitalopram Impairs Thrombin-Induced Platelet Response, Cytoskeletal Assembly and Activation of Associated Signalling Pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25689244" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Differential impact of selective serotonin reuptake inhibitors on platelet response to clopidogrel: a randomized, double-blind, crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12921813" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17107346" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33919295" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20456364" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Modern management of severe platelet function disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33124022" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The Use of Recombinant Activated Factor VII in Patients with Glanzmann's Thrombasthenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32868672" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Platelet transfusion for patients with platelet dysfunction: effectiveness, mechanisms, and unanswered questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25931584" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A systematic review of transfusion-associated graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12823748" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12411291" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12899721" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Activation of platelets in whole blood by recombinant factor VIIa by a thrombin-dependent mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14592825" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15456494" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35412688" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Iron deficiency anemia and bleeding management in pediatric patients with Bernard-Soulier syndrome and Glanzmann Thrombasthenia: A single-institution analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33625096" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Use of rFVIIa in Preventing Recurrent Intra-articular Hemorrhages in a 15-Year-Old Patient With Glanzmann Thrombasthenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33878047" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Weekly low-dose recombinant factor VIIa prophylaxis in Glanzmann thrombasthenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2293761" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Use of DDAVP in inherited and acquired platelet dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12414337" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Desmopressin in the treatment of patients with defects of platelet function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24443440" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10472549" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : [Thrombocytic alpha-delta-storage-pool-disease: shortening of bleeding time after infusion of 1-desamino-8-D-arginine vasopressin].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11925531" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Management of dental extractions in patients with bleeding disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33851983" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality: A Systematic Review, Meta-analysis, and Meta-regression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35436534" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Management of a Left Atrial Appendage Thrombus Due to Atrial Fibrillation Complicating Québec Platelet Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33205919" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Improved platelet counts during prolonged tranexamic therapy for Quebec platelet disorder implicate the underlying fibrinolytic defect as the cause of lower platelet counts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31273088" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33131064" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Efficacy of romiplostim in treatment of thrombocytopenia in children with Wiskott-Aldrich syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26224646" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29090586" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Diagnosis and treatment of MYH9-RD in an Australasian cohort with thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20844233" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34670170" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35100336" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35286390" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : How I manage pregnancy in women with Glanzmann thrombasthenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32997874" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Obstetrical bleeding in women with MYH9-related disease-A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18278172" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Congenital disorders associated with platelet dysfunctions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19656155" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : New insights into the haemostatic function of platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21467542" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21173099" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Clinical and genetic aspects of Bernard-Soulier syndrome: searching for genotype/phenotype correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21699652" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Molecular basis of Bernard-Soulier syndrome in 27 patients from India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28131619" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Patients with Bernard-Soulier syndrome and different severity of the bleeding phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21765412" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of plateletα-granules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17910626" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Platelet glycoprotein VI-related clinical defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32545517" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Linking the Landscape of MYH9-Related Diseases to the Molecular Mechanisms that Control Non-Muscle Myosin II-A Function in Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31384439" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : MYH9-related disease: it does exist, may be more frequent than you think and requires specific therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20174760" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Heavy chain myosin 9-related disease (MYH9 -RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35147601" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Characterization of Sensorineural Hearing Loss in Patients With MYH9-Related Disease: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32279414" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Guidance on the diagnosis and management of platelet-type von Willebrand disease: A communication from the Platelet Physiology Subcommittee of the ISTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18988861" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32663239" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Enhancer-gene rewiring in the pathogenesis of Quebec platelet disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6480825" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6480825" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21917754" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19234463" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9864781" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : [Pseudo-Glanzmann thrombasthenia in the course of autoimmune thrombocytopenic purpura].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1871709" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Acquired disorder of platelet function associated with autoantibodies against membrane glycoprotein IIb-IIIa complex--1. Glycoprotein analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15461628" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15720967" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The role of antiplatelet autoantibody assays in the diagnosis of immune thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16610580" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Clinical remission of acquired thrombasthenia with low-dose methotrexate in a patient with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2915873" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Bernard-Soulier syndrome complicating pregnancy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3055677" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Early immunization against platelet glycoprotein IIIa in a newborn Glanzmann type I patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37401038" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Acquired Glanzmann's thrombasthenia with IgG and IgA against activatedαIIbβ3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18205861" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Stem cell transplantation for children with Glanzmann thrombasthenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35198519" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Excellent Outcome Following Sibling Peripheral Blood Hematopoietic Stem Cell Transplantation for Glanzmann Thrombasthenia: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31693514" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Successful Use of Hematopoietic Stem Cell Transplantation for 2 Pediatric Cases of Glanzmann Thrombasthenia and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29152293" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23868573" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Indication for allogeneic stem cell transplantation in Glanzmann's thrombasthenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33147934" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19060241" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
